

Alzheimer's Disease: The Challenge of the Second Century

Science Translational Medicine

3, 77sr1

DOI: [10.1126/scitranslmed.3002369](https://doi.org/10.1126/scitranslmed.3002369)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Soluble A β 2 Seeds Are Potent Inducers of Cerebral β 2-Amyloid Deposition. <i>Journal of Neuroscience</i> , 2011, 31, 14488-14495.	1.7	203
2	Amyloid- β 2 forms fibrils by nucleated conformational conversion of oligomers. <i>Nature Chemical Biology</i> , 2011, 7, 602-609.	3.9	352
3	The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 698-712.	21.5	1,766
4	Resolving controversies on the path to Alzheimer's therapeutics. <i>Nature Medicine</i> , 2011, 17, 1060-1065.	15.2	434
5	Right sizing funding for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 17.	3.0	2
6	pH-Dependent Cu(II) Coordination to Amyloid- β 2 Peptide: Impact of Sequence Alterations, Including the H6R and D7N Familial Mutations.. <i>Inorganic Chemistry</i> , 2011, 50, 11192-11201.	1.9	73
7	The future of Alzheimer's disease: The next 10 years. <i>Progress in Neurobiology</i> , 2011, 95, 718-728.	2.8	190
8	The contribution of activated astrocytes to A β 2 production: Implications for Alzheimer's disease pathogenesis. <i>Journal of Neuroinflammation</i> , 2011, 8, 150.	3.1	278
9	Alzheimer's disease: synapses gone cold. <i>Molecular Neurodegeneration</i> , 2011, 6, 63.	4.4	250
10	Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders. <i>Annals of Neurology</i> , 2011, 70, 532-540.	2.8	536
12	Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid- β 2 Amyloidosis. <i>Journal of Neuroscience</i> , 2011, 31, 18007-18012.	1.7	166
13	Microtubule Affinity Regulating Kinase Activity in Living Neurons Was Examined by a Genetically Encoded Fluorescence Resonance Energy Transfer/Fluorescence Lifetime Imaging-based Biosensor. <i>Journal of Biological Chemistry</i> , 2011, 286, 41711-41722.	1.6	39
14	Phenylpiperidine-type β 3-secretase modulators target the transmembrane domain 1 of presenilin 1. <i>EMBO Journal</i> , 2011, 30, 4815-4824.	3.5	105
15	Synapses and Dendritic Spines as Pathogenic Targets in Alzheimer's Disease. <i>Neural Plasticity</i> , 2012, 2012, 1-8.	1.0	94
16	A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A β 2 on synapses and dendritic spines. <i>Human Molecular Genetics</i> , 2012, 21, 1384-1390.	1.4	94
17	Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of β 2-Amyloid in Mice with Alzheimer's Disease Pathology. <i>Science Translational Medicine</i> , 2012, 4, 150ra122.	5.8	454
18	Loss of Intranetwork and Internetwork Resting State Functional Connections with Alzheimer's Disease Progression. <i>Journal of Neuroscience</i> , 2012, 32, 8890-8899.	1.7	510
19	Generation of a novel murine model of A β 2 deposition based on the expression of human wild-type amyloid precursor protein gene. <i>Prion</i> , 2012, 6, 346-349.	0.9	0

#	ARTICLE	IF	CITATIONS
20	Beyond Amyloid. <i>Advances in Pharmacology</i> , 2012, 64, 213-271.	1.2	32
21	The Psen1 ϵ L166P knock-in mutation leads to amyloid deposition in human wild-type amyloid precursor protein YAC transgenic mice. <i>FASEB Journal</i> , 2012, 26, 2899-2910.	0.2	13
22	Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A β 2 amyloidosis. <i>Journal of Experimental Medicine</i> , 2012, 209, 2149-2156.	4.2	120
23	Contribution of the β -Secretase Subunits to the Formation of Catalytic Pore of Presenilin 1 Protein. <i>Journal of Biological Chemistry</i> , 2012, 287, 25834-25843.	1.6	28
24	Lipids in Alzheimer's disease and their potential for therapy. <i>Clinical Lipidology</i> , 2012, 7, 65-78.	0.4	12
25	CSF Biomarkers for Secondary Prevention Trials. <i>Archives of Neurology</i> , 2012, 69, 691-2.	4.9	2
26	Alzheimer's disease in a dish: promises and challenges of human stem cell models. <i>Human Molecular Genetics</i> , 2012, 21, R82-R89.	1.4	58
27	Translating Mendelian and complex inheritance of Alzheimer's disease genes for predicting unique personal genome variants. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2012, 19, 306-316.	2.2	18
28	Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases. <i>Current Genomics</i> , 2012, 13, 489-497.	0.7	20
29	Nonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy. <i>Current Pharmaceutical Design</i> , 2012, 18, 1159-1169.	0.9	120
30	Perspective. <i>Academic Medicine</i> , 2012, 87, 261-265.	0.8	24
32	Mass Spectrometric Characterization of Amyloid- β 2 Species in the 7PA2 Cell Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 85-93.	1.2	48
33	Neuropathological Basis of Alzheimer's Disease and Alzheimer's Disease Diagnosis. <i>Advances in Biological Psychiatry</i> , 2012, , 49-70.	0.2	1
34	Loss of Interleukin Receptor-Associated Kinase 4 Signaling Suppresses Amyloid Pathology and Alters Microglial Phenotype in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 15112-15123.	1.7	66
35	Insulin and IGF-1 signalling: longevity, protein homeostasis and Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2012, 40, 721-727.	1.6	117
36	Optimization of a Natural Product-Based Class of β -Secretase Modulators. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9270-9282.	2.9	44
37	Discovery of a Novel Pharmacological and Structural Class of Gamma Secretase Modulators Derived from the Extract of <i>Actaea racemosa</i> . <i>ACS Chemical Neuroscience</i> , 2012, 3, 941-951.	1.7	58
38	The Role of Natural Killer Cells in Alzheimer's Disease. <i>Scandinavian Journal of Immunology</i> , 2012, 76, 451-456.	1.3	31

#	ARTICLE	IF	CITATIONS
39	Use of proteomic methods in the analysis of human body fluids in Alzheimer research. <i>Electrophoresis</i> , 2012, 33, 3617-3630.	1.3	35
40	Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic Intervention. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S405-S416.	1.2	73
41	Toward a multifactorial model of Alzheimer disease. <i>Neurobiology of Aging</i> , 2012, 33, 2262-2271.	1.5	45
42	Initial Optimization of a New Series of β -Secretase Modulators Derived from a Triterpene Glycoside. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 908-913.	1.3	23
43	Preventing Alzheimer's Disease. <i>Science</i> , 2012, 337, 1488-1492.	6.0	328
44	PET amyloid-beta imaging in preclinical Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 370-379.	1.8	132
45	Coordination of redox active metal ions to the amyloid precursor protein and to amyloid- β peptides involved in Alzheimer disease. Part 2: Dependence of Cu(II) binding sites with $A\beta$ sequences. <i>Coordination Chemistry Reviews</i> , 2012, 256, 2175-2187.	9.5	129
46	Coordination of redox active metal ions to the amyloid precursor protein and to amyloid- β peptides involved in Alzheimer disease. Part 1: An overview. <i>Coordination Chemistry Reviews</i> , 2012, 256, 2164-2174.	9.5	149
47	Structural and functional characterization of H2 haplotype MAPT promoter: Unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease. <i>Gene</i> , 2012, 501, 63-78.	1.0	9
48	Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide. <i>Journal of Neuroscience</i> , 2012, 32, 15181-15192.	1.7	219
49	Phospho-dependent ubiquitination and degradation of PAR-1 regulates synaptic morphology and tau-mediated $A\beta$ toxicity in <i>Drosophila</i> . <i>Nature Communications</i> , 2012, 3, 1312.	5.8	49
50	Alzheimer's Disease. <i>Disease-a-Month</i> , 2012, 58, 666-677.	0.4	9
51	Neurodegeneration as an RNA disorder. <i>Progress in Neurobiology</i> , 2012, 99, 293-315.	2.8	52
52	Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease. <i>Brain Imaging and Behavior</i> , 2012, 6, 551-567.	1.1	66
53	Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. <i>Nature Reviews Neuroscience</i> , 2012, 13, 38-50.	4.9	568
54	Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling. <i>Molecular Neurodegeneration</i> , 2012, 7, 14.	4.4	23
55	Molecular Basis of Inhibitory Activities of Berberine against Pathogenic Enzymes in Alzheimer's Disease. <i>Scientific World Journal</i> , The, 2012, 2012, 1-4.	0.8	46
56	The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer's disease—old wine in new bottles. <i>Frontiers in Molecular Neuroscience</i> , 2012, 5, 20.	1.4	45

#	ARTICLE	IF	CITATIONS
57	Section summary and perspectives: Translational medicine in neurology. , 0, , 253-260.		0
58	Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of A β Uptake and Degradation by Astrocytes. <i>Journal of Biological Chemistry</i> , 2012, 287, 13959-13971.	1.6	152
59	An epigenetic blockade of cognitive functions in the neurodegenerating brain. <i>Nature</i> , 2012, 483, 222-226.	13.7	733
60	Interaction between pathogenic proteins in neurodegenerative disorders. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1166-1183.	1.6	104
61	Solid-state NMR Reveals a Close Structural Relationship between Amyloid- β Protofibrils and Oligomers. <i>Journal of Biological Chemistry</i> , 2012, 287, 22822-22826.	1.6	68
62	Exogenous seeding of cerebral β -amyloid deposition in β APP transgenic rats. <i>Journal of Neurochemistry</i> , 2012, 120, 660-666.	2.1	111
63	Twenty years of Alzheimer's disease-causing mutations. <i>Journal of Neurochemistry</i> , 2012, 120, 3-8.	2.1	123
64	miR-106b impairs cholesterol efflux and increases A β levels by repressing ABCA1 expression. <i>Experimental Neurology</i> , 2012, 235, 476-483.	2.0	161
65	Translational semantics and infrastructure: another search for the emperor's new clothes?. <i>Drug Discovery Today</i> , 2012, 17, 459-468.	3.2	29
66	Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal A β 42 accumulation and Caspase-3 activation. <i>Molecular Neurodegeneration</i> , 2013, 8, 2.	4.4	278
67	Straightforward synthesis of PET tracer precursors used for the early diagnosis of Alzheimer's disease through Suzuki-Miyaura cross-coupling reactions. <i>Tetrahedron</i> , 2013, 69, 7345-7353.	1.0	8
68	Design, synthesis and pharmacological evaluation of (E)-3,4-dihydroxy styryl sulfonamides derivatives as multifunctional neuroprotective agents against oxidative and inflammatory injury. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 5589-5597.	1.4	34
69	Ultrarapid Generation of Femtoliter Microfluidic Droplets for Single-Molecule-Counting Immunoassays. <i>ACS Nano</i> , 2013, 7, 5955-5964.	7.3	188
70	Therapeutic potential of GABAB receptor ligands in drug addiction, anxiety, depression and other CNS disorders. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 110, 174-184.	1.3	92
71	Olfactory Functions Scale with Circuit Restoration in a Rapidly Reversible Alzheimer's Disease Model. <i>Journal of Neuroscience</i> , 2013, 33, 12208-12217.	1.7	30
72	Genetics of Alzheimer Disease. , 2013, , 1-20.		0
73	Augmentation of Sensory-Evoked Hemodynamic Response in an Early Alzheimer's Disease Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 857-868.	1.2	16
74	Suppression of eIF2 γ kinases alleviates Alzheimer's disease-related plasticity and memory deficits. <i>Nature Neuroscience</i> , 2013, 16, 1299-1305.	7.1	486

#	ARTICLE	IF	CITATIONS
75	Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. <i>Nature</i> , 2013, 501, 45-51.	13.7	1,331
76	Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer A β Oligomer Bound to Cellular Prion Protein. <i>Neuron</i> , 2013, 79, 887-902.	3.8	485
77	Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms. <i>Epilepsy and Behavior</i> , 2013, 26, 343-351.	0.9	111
78	Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling. <i>Stem Cell Research</i> , 2013, 11, 1206-1221.	0.3	42
79	Synaptic deficits in layer 5 neurons precede overt structural decay in 5xFAD mice. <i>Neuroscience</i> , 2013, 254, 152-159.	1.1	51
80	FRET-Based Calcium Imaging: A Tool for High-Throughput/Content Phenotypic Drug Screening in Alzheimer Disease. <i>Journal of Biomolecular Screening</i> , 2013, 18, 1309-1320.	2.6	17
81	Biomarker Modeling of Alzheimer's Disease. <i>Neuron</i> , 2013, 80, 1347-1358.	3.8	773
82	The Choroid Plexus and Cerebrospinal Fluid: Emerging Roles in Development, Disease, and Therapy. <i>Journal of Neuroscience</i> , 2013, 33, 17553-17559.	1.7	151
83	The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. <i>Acta Neuropathologica</i> , 2013, 126, 479-497.	3.9	366
84	Biomarker utility in Alzheimer's disease clinical trials. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2013, 10, e55-e62.	0.5	1
85	Design, synthesis and evaluation of tacrine-flurbiprofen-nitrate trihybrids as novel anti-Alzheimer's disease agents. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2462-2470.	1.4	21
86	Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer's disease. <i>Clinical and Translational Imaging</i> , 2013, 1, 279-288.	1.1	3
87	SUMO and Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2013, 15, 720-736.	1.8	82
88	Copper ligation to soluble oligomers of the English mutant of the amyloid- β peptide yields a linear Cu(I) site that is resistant to O ₂ oxidation. <i>Chemical Communications</i> , 2013, 49, 4797.	2.2	12
89	Machine Learning-Based Method for Personalized and Cost-Effective Detection of Alzheimer's Disease. <i>IEEE Transactions on Biomedical Engineering</i> , 2013, 60, 164-168.	2.5	68
90	Zn impacts Cu coordination to amyloid- β , the Alzheimer's peptide, but not the ROS production and the associated cell toxicity. <i>Chemical Communications</i> , 2013, 49, 1214.	2.2	58
91	Histone acetylation: molecular mnemonics on the chromatin. <i>Nature Reviews Neuroscience</i> , 2013, 14, 97-111.	4.9	512
92	Investigating the binding interactions of galantamine with β -amyloid peptide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 239-243.	1.0	20

#	ARTICLE	IF	CITATIONS
93	Quantitative Imaging Biomarkers: The Application of Advanced Image Processing and Analysis to Clinical and Preclinical Decision Making. <i>Journal of Digital Imaging</i> , 2013, 26, 97-108.	1.6	65
94	Beta amyloid peptide plaques fail to alter evoked neuronal calcium signals in APP/PS1 Alzheimer's disease mice. <i>Neurobiology of Aging</i> , 2013, 34, 1632-1643.	1.5	20
95	Combination of A β clearance and neurotrophic factors as a potential treatment for Alzheimer's disease. <i>Neuroscience Bulletin</i> , 2013, 29, 111-120.	1.5	9
96	Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial. <i>Journal of Neuroscience</i> , 2013, 33, 4923-4934.	1.7	100
97	Developing Therapeutic Antibodies for Neurodegenerative Disease. <i>Neurotherapeutics</i> , 2013, 10, 459-472.	2.1	166
98	Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease. <i>Ageing Research Reviews</i> , 2013, 12, 116-140.	5.0	34
99	PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in aging, cognitive decline and Alzheimer's disease. <i>Experimental Gerontology</i> , 2013, 48, 647-653.	1.2	248
100	Molecular Pathology of the Central Nervous System. , 2013, , 357-405.		4
101	Brain Insulin Dysregulation: Implication for Neurological and Neuropsychiatric Disorders. <i>Molecular Neurobiology</i> , 2013, 47, 1045-1065.	1.9	93
102	The Prion-Like Aspect of Alzheimer Pathology. <i>Research and Perspectives in Alzheimer's Disease</i> , 2013, , 61-69.	0.1	2
103	Progress in gene therapy for neurological disorders. <i>Nature Reviews Neurology</i> , 2013, 9, 277-291.	4.9	202
104	Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis"but what lies beyond?. <i>Biochemical Pharmacology</i> , 2013, 85, 289-305.	2.0	181
105	Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. <i>FASEB Journal</i> , 2013, 27, 3239-3248.	0.2	57
106	Lipid raft disarrangement as a result of neuropathological progresses: A novel strategy for early diagnosis?. <i>Neuroscience</i> , 2013, 245, 26-39.	1.1	47
107	Structure-Activity Relationships and in Vivo Evaluation of Quinoxaline Derivatives for PET Imaging of β -Amyloid Plaques. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 596-600.	1.3	25
108	Peripherally Applied Synthetic Peptide isoAsp7-A β (1-42) Triggers Cerebral β -Amyloidosis. <i>Neurotoxicity Research</i> , 2013, 24, 370-376.	1.3	71
109	Axonal degeneration in Alzheimer's disease: When signaling abnormalities meet the axonal transport system. <i>Experimental Neurology</i> , 2013, 246, 44-53.	2.0	171
110	Modification of the Relationship of the Apolipoprotein E ϵ 4 Allele to the Risk of Alzheimer Disease and Neurofibrillary Tangle Density by Sleep. <i>JAMA Neurology</i> , 2013, 70, 1544.	4.5	216

#	ARTICLE	IF	CITATIONS
111	Amyloid- β oligomers regulate the properties of human neural stem cells through GSK-3 β signaling. <i>Experimental and Molecular Medicine</i> , 2013, 45, e60-e60.	3.2	58
112	Apolipoprotein E μ 4 Does Not Modulate Amyloid- β Associated Neurodegeneration in Preclinical Alzheimer Disease. <i>American Journal of Neuroradiology</i> , 2013, 34, 505-510.	1.2	16
113	An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment. <i>American Journal of Neuroradiology</i> , 2013, 34, 2075-2082.	1.2	24
114	The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE- μ 4 Carriers. <i>PLoS Genetics</i> , 2013, 9, e1003685.	1.5	55
115	ApoE influences amyloid- β ($A\beta$) clearance despite minimal apoE/ $A\beta$ association in physiological conditions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1807-16.	3.3	428
116	Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid- β secretion via deregulated lysosomal exocytosis. <i>Nature Communications</i> , 2013, 4, 2734.	5.8	109
117	In vivo characterization of a bigenic fluorescent mouse model of Alzheimer's disease with neurodegeneration. <i>Journal of Comparative Neurology</i> , 2013, 521, Spc1-Spc1.	0.9	4
118	In vivo characterization of a bigenic fluorescent mouse model of Alzheimer's disease with neurodegeneration. <i>Journal of Comparative Neurology</i> , 2013, 521, 2181-2194.	0.9	14
119	Context dependence of protein misfolding and structural strains in neurodegenerative diseases. <i>Biopolymers</i> , 2013, 100, 722-730.	1.2	13
120	Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3089-3094.	3.3	107
121	Processed B-Type Natriuretic Peptide Is a Biomarker of Postinterventional Restenosis in Ischemic Heart Disease. <i>Clinical Chemistry</i> , 2013, 59, 1330-1337.	1.5	14
122	C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease. <i>JAMA Neurology</i> , 2013, 70, 736.	4.5	92
123	Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 48.	3.0	115
124	Genetic Alzheimer's Disease. , 2013, , 232-233.		0
125	Learning and Memory. , 2013, , 1029-1051.		1
126	The Identification of Pathway Markers in Intracranial Aneurysm Using Genome-Wide Association Data from Two Different Populations. <i>PLoS ONE</i> , 2013, 8, e57022.	1.1	21
127	Neuroinflammation and Neuronal Loss Precede $A\beta$ Plaque Deposition in the hAPP-J20 Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e59586.	1.1	262
128	Quantitative Analysis of PIB-PET with FreeSurfer ROIs. <i>PLoS ONE</i> , 2013, 8, e73377.	1.1	192

#	ARTICLE	IF	CITATIONS
129	Development and Implementation of a High-Throughput Compound Screening Assay for Targeting Disrupted ER Calcium Homeostasis in Alzheimer's Disease. PLoS ONE, 2013, 8, e80645.	1.1	18
130	Cholinergic neuronsâ€”keeping check on amyloid β^2 in the cerebral cortex. Frontiers in Cellular Neuroscience, 2013, 7, 252.	1.8	7
131	Changes in White Matter Integrity before Conversion from Mild Cognitive Impairment to Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e106062.	1.1	32
132	CSF Biomarkers of Alzheimerâ€™s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. Advances in Geriatrics, 2014, 2014, 1-14.	1.6	15
133	Clinical Genetics of Alzheimerâ€™s Disease. BioMed Research International, 2014, 2014, 1-10.	0.9	39
134	Memory loss in Alzheimer's disease: are the alterations in the UPR network involved in the cognitive impairment?. Frontiers in Aging Neuroscience, 2014, 6, 8.	1.7	34
135	A comprehensive assessment of resting state networks: bidirectional modification of functional integrity in cerebro-cerebellar networks in dementia. Frontiers in Neuroscience, 2014, 8, 223.	1.4	67
136	Induced Pluripotent Stem Cells Derived from Alzheimerâ€™s Disease Patients: The Promise, the Hope and the Path Ahead. Journal of Clinical Medicine, 2014, 3, 1402-1436.	1.0	17
137	Role of LDL Cholesterol and Endolysosomes in Amyloidogenesis and Alzheimerâ€™s Disease. Journal of Neurology & Neurophysiology, 2014, 05, .	0.1	17
138	β^3 -Secretase Processing and Effects of β^3 -Secretase Inhibitors and Modulators on Long $A\beta^2$ Peptides in Cells. Journal of Biological Chemistry, 2014, 289, 3276-3287.	1.6	22
139	Identifying genetic interactions associated with late-onset Alzheimerâ€™s disease. BioData Mining, 2014, 7, 35.	2.2	16
140	Ocular Changes in TgF344-AD Rat Model of Alzheimer's Disease. , 2014, 55, 523.		125
141	Abundant kif21b is associated with accelerated progression in neurodegenerative diseases. Acta Neuropathologica Communications, 2014, 2, 144.	2.4	30
142	Allosteric regulation of β^3 -secretase activity by a phenylimidazole-type β^3 -secretase modulator. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10544-10549.	3.3	72
143	Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis of Alzheimer's disease by MRI. European Journal of Medicinal Chemistry, 2014, 87, 843-861.	2.6	45
144	The sleepâ€”wake cycle and Alzheimer's disease: what do we know?. Neurodegenerative Disease Management, 2014, 4, 351-362.	1.2	118
145	Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System. Frontiers in Endocrinology, 2014, 5, 142.	1.5	28
146	Role of Microglia Adenosine A2A Receptors in Retinal and Brain Neurodegenerative Diseases. Mediators of Inflammation, 2014, 2014, 1-13.	1.4	66

#	ARTICLE	IF	CITATIONS
147	Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders. <i>PLoS Computational Biology</i> , 2014, 10, e1003956.	1.5	151
148	Genome-Wide Association Study of CSF Levels of 59 Alzheimer's Disease Candidate Proteins: Significant Associations with Proteins Involved in Amyloid Processing and Inflammation. <i>PLoS Genetics</i> , 2014, 10, e1004758.	1.5	109
149	Population pharmacokinetic and pharmacodynamic analysis of plasma $A\beta_{40}$ and $A\beta_{42}$ following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 396-405.	0.8	13
150	The effect of neuropeptide Y on cell survival and neurotrophin expression in in-vitro models of Alzheimer's disease. <i>Canadian Journal of Physiology and Pharmacology</i> , 2014, 92, 621-630.	0.7	18
151	A Therapeutic Approach for Senile Dementias: Neuroangiogenesis. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1-17.	1.2	13
152	Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid. <i>Neurodegenerative Diseases</i> , 2014, 14, 98-106.	0.8	44
153	Modulation of Amyloid $A\beta$ Aggregation by Histidine-Coordinating Cobalt(III) Schiff Base Complexes. <i>ChemBioChem</i> , 2014, 15, 1584-1589.	1.3	37
154	Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1739-1742.	0.8	4
155	Effect of Potent β -Secretase Modulator in Human Neurons Derived From Multiple Presenilin 1-Induced Pluripotent Stem Cell Mutant Carriers. <i>JAMA Neurology</i> , 2014, 71, 1481.	4.5	84
156	Development and validation of the Greek Severe Impairment Battery (SIB). <i>International Psychogeriatrics</i> , 2014, 26, 591-596.	0.6	4
157	Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model. <i>Molecular Brain</i> , 2014, 7, 65.	1.3	104
158	BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 89.	3.0	322
159	Automatic classification of Alzheimer's disease with resting-state fMRI and graph theory. , 2014, , .		3
160	An Antidepressant Decreases CSF $A\beta$ Production in Healthy Individuals and in Transgenic AD Mice. <i>Science Translational Medicine</i> , 2014, 6, 236re4.	5.8	142
161	A Death Receptor 6-Amyloid Precursor Protein Pathway Regulates Synapse Density in the Mature CNS But Does Not Contribute to Alzheimer's Disease-Related Pathophysiology in Murine Models. <i>Journal of Neuroscience</i> , 2014, 34, 6425-6437.	1.7	48
162	Identification of tetrahydrocarbazoles as novel multifactorial drug candidates for treatment of Alzheimer's disease. <i>Translational Psychiatry</i> , 2014, 4, e489-e489.	2.4	15
163	Brain Intraventricular Injection of Amyloid- β in Zebrafish Embryo Impairs Cognition and Increases Tau Phosphorylation, Effects Reversed by Lithium. <i>PLoS ONE</i> , 2014, 9, e105862.	1.1	64
164	Effects of Diet on Brain Plasticity in Animal and Human Studies: Mind the Gap. <i>Neural Plasticity</i> , 2014, 2014, 1-32.	1.0	153

#	ARTICLE	IF	CITATIONS
165	Inhibition of AMP-Activated Protein Kinase Signaling Alleviates Impairments in Hippocampal Synaptic Plasticity Induced by Amyloid β . <i>Journal of Neuroscience</i> , 2014, 34, 12230-12238.	1.7	143
166	Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. <i>Human Molecular Genetics</i> , 2014, 23, 104-116.	1.4	224
167	Functional connectivity and graph theory in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 757-768.	1.5	318
168	Recent advances in the application of metabolomics to Alzheimer's Disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1232-1239.	1.8	149
169	Presenilin-1 Regulates the Expression of p62 to Govern p62-dependent Tau Degradation. <i>Molecular Neurobiology</i> , 2014, 49, 10-27.	1.9	11
170	Binding of longer β to transmembrane domain 1 of presenilin 1 impacts on β 42 generation. <i>Molecular Neurodegeneration</i> , 2014, 9, 7.	4.4	20
171	Differential Expression of Proteins in Brain Regions of Alzheimer's Disease Patients. <i>Neurochemical Research</i> , 2014, 39, 208-215.	1.6	30
172	REST and stress resistance in ageing and Alzheimer's disease. <i>Nature</i> , 2014, 507, 448-454.	13.7	648
173	The dendritic hypothesis for Alzheimer's disease pathophysiology. <i>Brain Research Bulletin</i> , 2014, 103, 18-28.	1.4	89
174	Protective Effect of Paeoniflorin on β 25-35-Induced SH-SY5Y Cell Injury by Preventing Mitochondrial Dysfunction. <i>Cellular and Molecular Neurobiology</i> , 2014, 34, 227-234.	1.7	90
175	Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. <i>Acta Neuropathologica Communications</i> , 2014, 2, 9.	2.4	138
176	Extracellular environment modulates the formation and propagation of particular amyloid structures. <i>Molecular Microbiology</i> , 2014, 92, 698-715.	1.2	20
177	The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model. <i>Brain Research</i> , 2014, 1551, 25-44.	1.1	30
178	Facilitated brain delivery of poly (ethylene glycol)-poly (lactic acid) nanoparticles by microbubble-enhanced unfocused ultrasound. <i>Biomaterials</i> , 2014, 35, 3384-3395.	5.7	49
179	Antioxidant gene therapy against neuronal cell death. , 2014, 142, 206-230.		120
180	An integrated study of the affinities of the β 16 peptide for Cu(I) and Cu(II): implications for the catalytic production of reactive oxygen species. <i>Metallomics</i> , 2014, 6, 505-517.	1.0	63
181	Human APOE genotype affects intraneuronal β 42 accumulation in a lentiviral gene transfer model. <i>Human Molecular Genetics</i> , 2014, 23, 1365-1375.	1.4	35
182	Neuroinflammation and Alzheimer's disease: lessons learned from 5-lipoxygenase. <i>Translational Neuroscience</i> , 2014, 5, .	0.7	11

#	ARTICLE	IF	CITATIONS
183	Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 2457-2467.	1.8	14
184	Highly potent soluble amyloid- β^2 seeds in human Alzheimer brain but not cerebrospinal fluid. <i>Brain</i> , 2014, 137, 2909-2915.	3.7	61
185	Specific aromatic foldamers potently inhibit spontaneous and seeded A β^{242} and A β^{243} fibril assembly. <i>Biochemical Journal</i> , 2014, 464, 85-98.	1.7	13
186	Anti-ApoE Antibody Given after Plaque Onset Decreases A β^2 Accumulation and Improves Brain Function in a Mouse Model of A β^2 Amyloidosis. <i>Journal of Neuroscience</i> , 2014, 34, 7281-7292.	1.7	102
187	Use of a new water-soluble Zn sensor to determine Zn affinity for the amyloid- β^2 peptide and relevant mutants. <i>Metallomics</i> , 2014, 6, 1220.	1.0	36
188	Deficiency in LRP6-Mediated Wnt Signaling Contributes to Synaptic Abnormalities and Amyloid Pathology in Alzheimer's Disease. <i>Neuron</i> , 2014, 84, 63-77.	3.8	168
189	Single-Walled Carbon Nanotubes Alleviate Autophagic/Lysosomal Defects in Primary Glia from a Mouse Model of Alzheimer's Disease. <i>Nano Letters</i> , 2014, 14, 5110-5117.	4.5	109
190	Early remodeling of the neocortex upon episodic memory encoding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11852-11857.	3.3	86
191	Reduction of Amyloid- β^2 Deposition and Attenuation of Memory Deficits by Tolfenamic Acid. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 425-433.	1.2	16
192	A genome-wide association study combining pathway analysis for typical sporadic amyotrophic lateral sclerosis in Chinese Han populations. <i>Neurobiology of Aging</i> , 2014, 35, 1778.e9-1778.e23.	1.5	49
193	Alzheimer's Disease Genetics: From the Bench to the Clinic. <i>Neuron</i> , 2014, 83, 11-26.	3.8	396
194	Grey-matter volume as a potential feature for the classification of Alzheimer's disease and mild cognitive impairment: an exploratory study. <i>Neuroscience Bulletin</i> , 2014, 30, 477-489.	1.5	45
195	Fibril Elongation by A β^{17-42} : Kinetic Network Analysis of Hybrid-Resolution Molecular Dynamics Simulations. <i>Journal of the American Chemical Society</i> , 2014, 136, 12450-12460.	6.6	127
196	Phosphorylated Tau-A β^{242} Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer's Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid. <i>Biological Psychiatry</i> , 2014, 75, 723-731.	0.7	72
197	Brainwide distribution and variance of amyloid-beta deposits in tg-ArcSwe mice. <i>Neurobiology of Aging</i> , 2014, 35, 556-564.	1.5	19
198	Expression of A2V-mutated A β^2 in <i>Caenorhabditis elegans</i> results in oligomer formation and toxicity. <i>Neurobiology of Disease</i> , 2014, 62, 521-532.	2.1	30
199	Flavonoids as Therapeutic Compounds Targeting Key Proteins Involved in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2014, 5, 83-92.	1.7	151
200	Young blood rejuvenates old brains. <i>Nature Medicine</i> , 2014, 20, 582-583.	15.2	6

#	ARTICLE	IF	CITATIONS
201	Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies. <i>Neuron</i> , 2014, 82, 1271-1288.	3.8	822
202	Epigenetic regulation of estrogen-dependent memory. <i>Frontiers in Neuroendocrinology</i> , 2014, 35, 530-549.	2.5	56
203	Insulin protects against A β -induced spatial memory impairment, hippocampal apoptosis and MAPKs signaling disruption. <i>Neuropharmacology</i> , 2014, 85, 113-120.	2.0	61
204	Meta-analysis of PvuII, XbaI variants in ESR1 gene and the risk of Alzheimer's disease: The regional European difference. <i>Neuroscience Letters</i> , 2014, 574, 41-46.	1.0	16
205	The role of N-methyl-D-aspartate receptor in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2014, 339, 123-129.	0.3	8
206	Targeting the β secretase BACE1 for Alzheimer's disease therapy. <i>Lancet Neurology</i> , The, 2014, 13, 319-329.	4.9	527
207	APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. <i>Molecular Psychiatry</i> , 2014, 19, 351-357.	4.1	181
208	Research progress in animal models and stem cell therapy for Alzheimer's disease. <i>Journal of Neurorestoration</i> , 0, , 11.	1.1	5
209	GSK3 in Alzheimer's Disease: Mind the Isoforms. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 707-710.	1.2	60
210	Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults.. <i>Neuropsychology</i> , 2015, 29, 368-381.	1.0	24
211	Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 411-424.	1.2	76
212	Increased CSF A β during the very early phase of cerebral A β deposition in mouse models. <i>EMBO Molecular Medicine</i> , 2015, 7, 895-903.	3.3	42
213	Human neural stem cells alleviate Alzheimer-like pathology in a mouse model. <i>Molecular Neurodegeneration</i> , 2015, 10, 38.	4.4	120
214	Direct and Indirect Interventions for Cognitive-Communication Disorders of Dementia. <i>Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders</i> , 2015, 25, 142-157.	0.4	3
215	Current Versus Lifetime Depression, APOE Variation, and Their Interaction on Cognitive Performance in Younger and Older Adults. <i>Psychosomatic Medicine</i> , 2015, 77, 480-492.	1.3	11
216	Dextran sulfate sodium inhibits amyloid β oligomer binding to cellular prion protein. <i>Journal of Neurochemistry</i> , 2015, 134, 611-617.	2.1	11
217	Genetic Markers in Biological Fluids for Aging-Related Major Neurocognitive Disorder. <i>Current Alzheimer Research</i> , 2015, 12, 200-209.	0.7	8
218	The Function of Autophagy in Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2015, 16, 26797-26812.	1.8	129

#	ARTICLE	IF	CITATIONS
219	Caffeine, Through Adenosine A3 Receptor-Mediated Actions, Suppresses Amyloid- β Protein Precursor Internalization and Amyloid- β Generation. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 73-83.	1.2	27
220	The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 436.	1.8	60
221	Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. <i>Frontiers in Neurology</i> , 2015, 6, 142.	1.1	25
222	Quantitative Amyloid Imaging Using Image-Derived Arterial Input Function. <i>PLoS ONE</i> , 2015, 10, e0122920.	1.1	30
223	Cerebral β -Amyloidosis in Mice Investigated by Ultramicroscopy. <i>PLoS ONE</i> , 2015, 10, e0125418.	1.1	26
224	Screening Flavonoids for Inhibition of Acetylcholinesterase Identified Baicalein as the Most Potent Inhibitor. <i>Journal of Agricultural Science</i> , 2015, 7, .	0.1	32
225	The Peptide Vaccine Combined with Prior Immunization of a Conventional Diphtheria-Tetanus Toxoid Vaccine Induced Amyloid- β Binding Antibodies on Cynomolgus Monkeys and Guinea Pigs. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	0.9	5
226	Association study in Alzheimer's disease of single nucleotide polymorphisms implicated with coffee consumption. <i>Revista De Psiquiatria Clinica</i> , 2015, 42, 69-73.	0.6	4
227	Hyperglycemia modulates extracellular amyloid- β concentrations and neuronal activity in vivo. <i>Journal of Clinical Investigation</i> , 2015, 125, 2463-2467.	3.9	165
228	Systems biology of neurodegenerative diseases. <i>Integrative Biology (United Kingdom)</i> , 2015, 7, 758-775.	0.6	40
229	Synthesis of chemically-tethered amyloid- β segment trimer possessing amyloidogenic properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2976-2979.	1.0	16
230	Cognitive Improvements in a Mouse Model with Substituted 1,2,3-Triazole Agonists for Nicotinic Acetylcholine Receptors. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1331-1340.	1.7	13
231	Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation. <i>American Journal of Neuroradiology</i> , 2015, 36, 1237-1244.	1.2	40
232	Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation. <i>Cell Reports</i> , 2015, 11, 1176-1183.	2.9	206
233	Study on the Feasibility of Using a Chinese Character Writing Scale to Distinguish Amnestic-MCI. , 2015, , .		0
234	Detection and Quantification of β -Amyloid, Pyroglutamy β , and Tau in Aged Canines. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 912-923.	0.9	56
235	Reduced cortical BACE1 content with one bout of exercise is accompanied by declines in AMPK, Akt, and MAPK signaling in obese, glucose-intolerant mice. <i>Journal of Applied Physiology</i> , 2015, 119, 1097-1104.	1.2	53
236	Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APP ^{swE} /PS1 ^{dE9} mice. <i>Acta Neuropathologica Communications</i> , 2015, 3, 54.	2.4	38

#	ARTICLE	IF	CITATIONS
237	Natural Î ² -Dihydroagarofuran-Type Sesquiterpenoids as Cognition-Enhancing and Neuroprotective Agents from Medicinal Plants of the Genus <i>Celastrus</i> . <i>Journal of Natural Products</i> , 2015, 78, 2175-2186.	1.5	42
238	Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 40, 54-62.	0.7	21
239	Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with preclinical AD, amnesic mild cognitive impairment and late-stage AD. <i>Journal of Neurochemistry</i> , 2015, 133, 739-749.	2.1	276
240	Bridging Integrator 1 (BIN1) Genotype Effects on Working Memory, Hippocampal Volume, and Functional Connectivity in Young Healthy Individuals. <i>Neuropsychopharmacology</i> , 2015, 40, 1794-1803.	2.8	55
241	Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-Î ² in an APP transgenic mouse model. <i>Brain, Behavior, and Immunity</i> , 2015, 47, 163-171.	2.0	12
242	Progression of Seed-Induced AÎ ² Deposition within the Limbic Connectome. <i>Brain Pathology</i> , 2015, 25, 743-752.	2.1	45
243	Telencephalic neurocircuitry and synaptic plasticity in rodent spatial learning and memory. <i>Brain Research</i> , 2015, 1621, 294-308.	1.1	14
244	Cooperative Roles of Hydrophilic Loop 1 and the C-Terminus of Presenilin 1 in the Substrate-Gating Mechanism of Î ³ -Secretase. <i>Journal of Neuroscience</i> , 2015, 35, 2646-2656.	1.7	48
245	Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. <i>Annals of Neurology</i> , 2015, 77, 953-971.	2.8	282
246	Decrease in catalytic capacity of Î ³ -secretase can facilitate pathogenesis in sporadic and Familial Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2015, 67, 55-65.	1.0	15
247	Reducing AÎ ² load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2015, 764, 571-581.	1.7	42
248	Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3699-708.	3.3	313
249	Will PET Amyloid Imaging Lead to Overdiagnosis of Alzheimer Dementia?. <i>Academic Radiology</i> , 2015, 22, 988-994.	1.3	9
250	Nicotinic Acetylcholine Receptors Sensitize a MAPK-linked Toxicity Pathway on Prolonged Exposure to Î ² -Amyloid. <i>Journal of Biological Chemistry</i> , 2015, 290, 21409-21420.	1.6	20
251	Intraventricular Delivery of siRNA Nanoparticles to the Central Nervous System. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e242.	2.3	43
252	Neuronal hyperactivity - A key defect in Alzheimer's disease?. <i>BioEssays</i> , 2015, 37, 624-632.	1.2	182
253	Hologram QSAR Models of a Series of 6-Arylquinazolin-4-Amine Inhibitors of a New Alzheimer's Disease Target: Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase-1A Enzyme. <i>International Journal of Molecular Sciences</i> , 2015, 16, 5235-5253.	1.8	12
254	Identifying patients with Alzheimer's disease using resting-state fMRI and graph theory. <i>Clinical Neurophysiology</i> , 2015, 126, 2132-2141.	0.7	181

#	ARTICLE	IF	CITATIONS
255	Sleep Restores Behavioral Plasticity to Drosophila Mutants. <i>Current Biology</i> , 2015, 25, 1270-1281.	1.8	116
256	Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 5225-5230.	3.3	120
257	Modulation of Mitochondrial Complex I Activity Averts Cognitive Decline in Multiple Animal Models of Familial Alzheimer's Disease. <i>EBioMedicine</i> , 2015, 2, 294-305.	2.7	87
258	Haptoglobin Modulates Beta-Amyloid Uptake by U-87 MG Astrocyte Cell Line. <i>Journal of Molecular Neuroscience</i> , 2015, 56, 35-47.	1.1	14
259	Brain aerobic glycolysis functions and Alzheimer's disease. <i>Clinical and Translational Imaging</i> , 2015, 3, 27-37.	1.1	71
260	Roles of zinc ions and structural polymorphism of β -amyloid in the development of Alzheimer's disease. <i>Molecular Biology</i> , 2015, 49, 217-230.	0.4	27
261	Effects of CD2-associated protein deficiency on amyloid- β in neuroblastoma cells and in an APP transgenic mouse model. <i>Molecular Neurodegeneration</i> , 2015, 10, 12.	4.4	37
262	mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. <i>Neurobiology of Disease</i> , 2015, 84, 39-49.	2.1	261
263	Is there a link between the sleep-wake cycle and Alzheimer's pathology?. <i>Future Neurology</i> , 2015, 10, 183-186.	0.9	1
264	Neurodegenerative Diseases: Expanding the Prion Concept. <i>Annual Review of Neuroscience</i> , 2015, 38, 87-103.	5.0	278
265	Copper targeting in the Alzheimer's disease context: a first example using the biocompatible PTA ligand. <i>Metallomics</i> , 2015, 7, 1229-1232.	1.0	35
266	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. <i>Neurobiology of Aging</i> , 2015, 36, 1771-1779.	1.5	36
267	Multiple Function Fluorescein Probe Performs Metal Chelation, Disaggregation, and Modulation of Aggregated $A\beta$ and $A\beta$ -Cu Complex. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1880-1891.	1.7	35
268	Destruction of amyloid fibrils by graphene through penetration and extraction of peptides. <i>Nanoscale</i> , 2015, 7, 18725-18737.	2.8	101
269	Replacement of brain-resident myeloid cells does not alter cerebral amyloid- β deposition in mouse models of Alzheimer's disease. <i>Journal of Experimental Medicine</i> , 2015, 212, 1803-1809.	4.2	81
270	Studying the relationship between cell cycle and Alzheimer's disease by gold nanoparticle probes. <i>Analytical Biochemistry</i> , 2015, 489, 32-37.	1.1	6
271	Amyloid- β pathology induced in humans. <i>Nature</i> , 2015, 525, 193-194.	13.7	43
272	Isolation Housing Exacerbates Alzheimer's Disease-Like Pathophysiology in Aged APP/PS1 Mice. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu116-pyu116.	1.0	62

#	ARTICLE	IF	CITATIONS
273	Targeting protein aggregation for the treatment of degenerative diseases. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 759-780.	21.5	338
274	Transport of cargo from periphery to brain by circulating monocytes. <i>Brain Research</i> , 2015, 1622, 328-338.	1.1	14
275	Histone H3 Ser57 and Thr58 phosphorylation in the brain of 5XFAD mice. <i>FEBS Open Bio</i> , 2015, 5, 550-556.	1.0	25
276	Recent Advances from the Bench Toward the Bedside in Alzheimer's Disease. <i>EBioMedicine</i> , 2015, 2, 94-95.	2.7	5
277	The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and A β amyloidosis. <i>Science Translational Medicine</i> , 2015, 7, 314ra184.	5.8	30
278	Partial volume correction in quantitative amyloid imaging. <i>NeuroImage</i> , 2015, 107, 55-64.	2.1	188
279	Alzheimer's Disease Risk Genes and Mechanisms of Disease Pathogenesis. <i>Biological Psychiatry</i> , 2015, 77, 43-51.	0.7	1,034
280	Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis. <i>Neurobiology of Aging</i> , 2015, 36, 42-52.	1.5	78
281	At the interface of sensory and motor dysfunctions and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 70-98.	0.4	420
282	MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons. <i>Molecular Neurobiology</i> , 2016, 53, 95-108.	1.9	48
283	Autophagy: machinery and regulation. <i>Microbial Cell</i> , 2016, 3, 588-596.	1.4	461
284	Impact of SORL1 genetic variations on MRI markers in non-demented elders. <i>Oncotarget</i> , 2016, 7, 31689-31698.	0.8	8
285	Shanghai Cohort Study on Mild Cognitive Impairment: Study Design and Baseline Characteristics. , 2016, 06, .		3
286	The Anti-Prion Antibody 15B3 Detects Toxic Amyloid- β Oligomers. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1485-1497.	1.2	12
287	Generation of Cholinergic and Dopaminergic Interneurons from Human Pluripotent Stem Cells as a Relevant Tool for In Vitro Modeling of Neurological Disorders Pathology and Therapy. <i>Stem Cells International</i> , 2016, 2016, 1-16.	1.2	10
288	Role of Endolysosomes in Skeletal Muscle Pathology Observed in a Cholesterol-Fed Rabbit Model of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 129.	1.7	5
289	In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's A β protein. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 223.	1.7	34
290	Immununochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases. <i>Frontiers in Neurology</i> , 2016, 7, 195.	1.1	25

#	ARTICLE	IF	CITATIONS
291	Predicting Progression from Mild Cognitive Impairment to Alzheimer's Dementia Using Clinical, MRI, and Plasma Biomarkers via Probabilistic Pattern Classification. PLoS ONE, 2016, 11, e0138866.	1.1	157
292	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	1.1	45
293	Behavioural Phenotyping of APP ^{swe} /PS1 ^{E9} Mice: Age-Related Changes and Effect of Long-Term Paroxetine Treatment. PLoS ONE, 2016, 11, e0165144.	1.1	34
294	Lipid Raft Size and Lipid Mobility in Non-raft Domains Increase during Aging and Are Exacerbated in APP/PS1 Mice Model of Alzheimer's Disease. Predictions from an Agent-Based Mathematical Model. Frontiers in Physiology, 2016, 7, 90.	1.3	23
295	Deep Phosphoproteomic Measurements Pinpointing Drug Induced Protective Mechanisms in Neuronal Cells. Frontiers in Physiology, 2016, 7, 635.	1.3	6
296	Substrate recruitment of β -secretase and mechanism of clinical presenilin mutations revealed by photoaffinity mapping. EMBO Journal, 2016, 35, 1628-1643.	3.5	104
297	miR-186 is decreased in aged brain and suppresses β -secretase expression. Journal of Neurochemistry, 2016, 137, 436-445.	2.1	78
298	Dual-specificity phosphatase 26 (DUSP26) stimulates $A\beta$ 42 generation by promoting amyloid precursor protein axonal transport during hypoxia. Journal of Neurochemistry, 2016, 137, 770-781.	2.1	20
299	Is ApoE ϵ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?. Translational Neurodegeneration, 2016, 5, 20.	3.6	15
300	Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases. Annual Review of Genetics, 2016, 50, 329-346.	3.2	53
301	Different Expression Patterns of Amyloid- β 2 Protein Precursor Secretases in Human and Mouse Hippocampal Neurons: A Potential Contribution to Species Differences in Neuronal Susceptibility to Amyloid- β Pathogenesis. Journal of Alzheimer's Disease, 2016, 51, 179-195.	1.2	5
302	Anti-Viral Properties of Amyloid- β 2 Peptides. Journal of Alzheimer's Disease, 2016, 54, 859-878.	1.2	70
303	Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration. Journal of Alzheimer's Disease, 2016, 52, 179-190.	1.2	39
304	MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 2139-2147.	1.2	18
305	Resveratrol Attenuates $A\beta$ 25-35 Caused Neurotoxicity by Inducing Autophagy Through the TyrRS-PARP1-SIRT1 Signaling Pathway. Neurochemical Research, 2016, 41, 2367-2379.	1.6	73
306	TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. Journal of Experimental Medicine, 2016, 213, 667-675.	4.2	565
307	Inhibitory effect of flavonoids on human glutaminyl cyclase. Bioorganic and Medicinal Chemistry, 2016, 24, 2280-2286.	1.4	23
308	5-Hydroxymethylation-associated epigenetic modifiers of Alzheimer's disease modulate Tau-induced neurotoxicity. Human Molecular Genetics, 2016, 25, dww109.	1.4	53

#	ARTICLE	IF	CITATIONS
309	Modulation of Amyloid Aggregates into Nontoxic Coaggregates by Hydroxyquinoline Appended Polyfluorene. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 13309-13319.	4.0	21
310	Physiological Role of Autophagy and Implications in Disease. , 2016, , 51-80.		0
311	Conversion of Synthetic A β 2 to <i>In Vivo</i> Active Seeds and Amyloid Plaque Formation in a Hippocampal Slice Culture Model. <i>Journal of Neuroscience</i> , 2016, 36, 5084-5093.	1.7	41
312	How Zn can impede Cu detoxification by chelating agents in Alzheimer's disease: a proof-of-concept study. <i>Dalton Transactions</i> , 2016, 45, 15671-15678.	1.6	33
313	Zinc(II) Binding Site to the Amyloid- β 2 Peptide: Insights from Spectroscopic Studies with a Wide Series of Modified Peptides. <i>Inorganic Chemistry</i> , 2016, 55, 10499-10509.	1.9	74
314	Expression of Alzheimer's disease risk genes in ischemic brain degeneration. <i>Pharmacological Reports</i> , 2016, 68, 1345-1349.	1.5	15
315	Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective. <i>Brain Pathology</i> , 2016, 26, 664-671.	2.1	5
316	High-Molecular-Weight Paired Helical Filaments from Alzheimer Brain Induces Seeding of Wild-Type Mouse Tau into an Argyrophilic 4R Tau Pathology <i>In Vivo</i> . <i>American Journal of Pathology</i> , 2016, 186, 2709-2722.	1.9	51
317	Meta-analysis of cyclooxygenase-2 (COX-2) 765G>C polymorphism and Alzheimer's disease. <i>Journal of Clinical Neuroscience</i> , 2016, 31, 4-9.	0.8	2
318	Long-term caloric restriction in mice may prevent age-related learning impairment via suppression of apoptosis. <i>Behavioural Brain Research</i> , 2016, 315, 45-50.	1.2	9
319	Translational control by eIF2 γ in neurons: Beyond the stress response. <i>Cytoskeleton</i> , 2016, 73, 551-565.	1.0	38
320	Non-Fibrillar Oligomeric Amyloid- β 2 within Synapses. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 787-800.	1.2	65
321	Hydrogen sulfide ameliorates learning memory impairment in APP/PS1 transgenic mice: A novel mechanism mediated by the activation of Nrf2. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 150-151, 207-216.	1.3	56
322	Medicinal Chemistry Focusing on Aggregation of Amyloid- β 2. <i>Chemical and Pharmaceutical Bulletin</i> , 2016, 64, 1-7.	0.6	15
323	Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 42, 146-158.	0.7	40
324	Localization of zinc binding sites of Ab1-16 with English mutation during formation of monomers and dimers with zinc. <i>International Journal of Mass Spectrometry</i> , 2016, 409, 67-72.	0.7	3
325	Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?. <i>Journal of Experimental Medicine</i> , 2016, 213, 1375-1385.	4.2	153
326	The Genetic Basis of Alzheimer's Disease. , 2016, , 547-571.		5

#	ARTICLE	IF	CITATIONS
327	Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice. <i>Age</i> , 2016, 38, 303-322.	3.0	53
328	Three-Dimensional Study of Alzheimer's Disease Hallmarks Using the iDISCO Clearing Method. <i>Cell Reports</i> , 2016, 16, 1138-1152.	2.9	156
329	The Effects of Peripheral and Central High Insulin on Brain Insulin Signaling and Amyloid- β^2 in Young and Old APP/PS1 Mice. <i>Journal of Neuroscience</i> , 2016, 36, 11704-11715.	1.7	58
330	Depletion of TDP-43 decreases fibril and plaque β^2 -amyloid and exacerbates neurodegeneration in an Alzheimer's mouse model. <i>Acta Neuropathologica</i> , 2016, 132, 859-873.	3.9	43
331	The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model. <i>Nature Communications</i> , 2016, 7, 12082.	5.8	56
332	Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke. <i>Scientific Reports</i> , 2016, 6, 25626.	1.6	14
333	A protein homeostasis signature in healthy brains recapitulates tissue vulnerability to Alzheimer's disease. <i>Science Advances</i> , 2016, 2, e1600947.	4.7	84
334	Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. <i>Scientific Reports</i> , 2016, 6, 26027.	1.6	48
335	Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid- β^2 clearance and aggregation in Alzheimer's disease. <i>Science Translational Medicine</i> , 2016, 8, 332ra44.	5.8	115
336	Unspecific binding of cRNA probe to plaques in two mouse models for Alzheimer's disease. <i>Journal of Negative Results in BioMedicine</i> , 2016, 15, 22.	1.4	0
337	Heterogeneous multimodal biomarkers analysis for Alzheimer's disease via Bayesian network. <i>Eurasip Journal on Bioinformatics and Systems Biology</i> , 2016, 2016, 12.	1.4	18
338	β^2 -Secretase Inhibition. , 2016, , 39-62.		2
339	The Prion-Like Properties of Amyloid- β^2 Assemblies: Implications for Alzheimer's Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a024398.	2.9	71
340	Active Immunization Against the Amyloid- β^2 Peptide. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 19-35.	0.1	0
341	Loss of ceramide synthase 2 activity, necessary for myelin biosynthesis, precedes tau pathology in the cortical pathogenesis of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 43, 89-100.	1.5	68
342	Comparative pathobiology of β^2 -amyloid and the unique susceptibility of humans to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 44, 185-196.	1.5	34
343	Significantly enhanced proteolytic activity of cyclen complexes by monoalkylation. <i>Dalton Transactions</i> , 2016, 45, 10500-10504.	1.6	8
344	The anti-dementia drug candidate, (β^2)-clausenamide, improves memory impairment through its multi-target effect. , 2016, 162, 179-187.		37

#	ARTICLE	IF	CITATIONS
345	Preliminary evidence of altered steroidogenesis in women with Alzheimer's disease: Have the patients "OLDER" adrenal zona reticularis?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 158, 157-177.	1.2	20
346	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016, 139, 922-936.	3.7	235
347	Impaired Eukaryotic Elongation Factor 1A Expression in Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2016, 16, 39-43.	0.8	23
348	The new β^2 amyloid-derived peptide A β 1-6A2V-TAT(D) prevents A β oligomer formation and protects transgenic <i>C. elegans</i> from A β toxicity. <i>Neurobiology of Disease</i> , 2016, 88, 75-84.	2.1	17
349	Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 405-412.	0.9	17
350	Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting A β amyloid aggregates. <i>Journal of Biological Inorganic Chemistry</i> , 2016, 21, 83-99.	1.1	19
351	The 5-Lipoxygenase as modulator of Alzheimer's β -secretase and therapeutic target. <i>Brain Research Bulletin</i> , 2016, 126, 207-212.	1.4	24
352	Association Between Serum Triglycerides and Cerebral Amyloidosis in Cognitively Normal Elderly. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 604-612.	0.6	17
353	The cell-permeable A β 1-6A2VTAT(D) peptide reverts synaptopathy induced by A β 1-42wt. <i>Neurobiology of Disease</i> , 2016, 89, 101-111.	2.1	19
354	Conformational Changes in Transmembrane Domain 4 of Presenilin 1 Are Associated with Altered Amyloid- β 42 Production. <i>Journal of Neuroscience</i> , 2016, 36, 1362-1372.	1.7	25
355	The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. <i>Brain Research</i> , 2016, 1634, 158-170.	1.1	67
356	TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. <i>Nature Reviews Neuroscience</i> , 2016, 17, 201-207.	4.9	312
357	Role of docosahexaenoic acid in the modulation of glial cells in Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2016, 13, 61.	3.1	68
358	Vascular and Metabolic Factors in Alzheimer's Disease and Related Dementias: Introduction. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 151-154.	1.7	42
359	Alzheimer's Disease and the Sleep-Wake Cycle. , 2016, , 295-317.		0
360	Valproic acid ameliorates olfactory dysfunction in APP/PS1 transgenic mice of Alzheimer's disease: Ameliorations from the olfactory epithelium to the olfactory bulb. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 144, 53-59.	1.3	14
361	Changes in astrocyte functional markers and β -amyloid metabolism-related proteins in the early stages of hypercholesterolemia. <i>Neuroscience</i> , 2016, 316, 178-191.	1.1	37
362	Therapeutic strategies for Alzheimer's disease in clinical trials. <i>Pharmacological Reports</i> , 2016, 68, 127-138.	1.5	357

#	ARTICLE	IF	CITATIONS
363	Endothelial Dysfunction and Amyloid- β -Induced Neurovascular Alterations. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 155-165.	1.7	85
364	The Role of PGRN in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 4189-4196.	1.9	20
365	Thiosemicarbazone modification of 3-acetyl coumarin inhibits A β peptide aggregation and protect against A β -induced cytotoxicity. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 803-809.	2.6	35
366	Amyloid- β induces sleep fragmentation that is rescued by fatty acid binding proteins in <i>Drosophila</i> . <i>Journal of Neuroscience Research</i> , 2017, 95, 1548-1564.	1.3	28
367	Scandium(III) triflate-promoted serine/threonine-selective peptide bond cleavage. <i>Chemical Communications</i> , 2017, 53, 3311-3314.	2.2	17
368	Antibody Therapeutics Targeting A β and Tau. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a024331.	2.9	39
369	Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1105-1121.	1.2	1,123
370	Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. <i>Acta Neuropathologica</i> , 2017, 133, 785-807.	3.9	67
371	Chronic Sleep Restriction Induces Cognitive Deficits and Cortical Beta-Amyloid Deposition in Mice via BACE1 Antisense Activation. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 233-240.	1.9	39
372	Targeting β -amyloid plaques and oligomers: development of near-IR fluorescence imaging probes. <i>Future Medicinal Chemistry</i> , 2017, 9, 179-198.	1.1	23
373	Disease-Modifying Effects of M ₁ Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1177-1187.	1.7	36
374	Chronic Lithium Treatment in a Rat Model of Basal Forebrain Cholinergic Depletion: Effects on Memory Impairment and Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1505-1518.	1.2	7
375	Amyloid- β Oligomers Interact with Neurexin and Diminish Neurexin-mediated Excitatory Presynaptic Organization. <i>Scientific Reports</i> , 2017, 7, 42548.	1.6	29
376	Polo-like kinase 2 phosphorylation of amyloid precursor protein regulates activity-dependent amyloidogenic processing. <i>Neuropharmacology</i> , 2017, 117, 387-400.	2.0	21
377	Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease. <i>Molecular Therapy</i> , 2017, 25, 752-764.	3.7	82
378	TREM2, Microglia, and Neurodegenerative Diseases. <i>Trends in Molecular Medicine</i> , 2017, 23, 512-533.	3.5	327
379	Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	78
380	Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease. <i>Journal of Controlled Release</i> , 2017, 258, 121-129.	4.8	40

#	ARTICLE	IF	CITATIONS
381	Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony. <i>Trends in Neurosciences</i> , 2017, 40, 347-357.	4.2	327
382	Novel Benzothiazole Derivatives as Fluorescent Probes for Detection of β -Amyloid and τ -Synuclein Aggregates. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1656-1662.	1.7	48
383	Identification of key structural features of the elusive Cu ⁺ -A β complex that generates ROS in Alzheimer's disease. <i>Chemical Science</i> , 2017, 8, 5107-5118.	3.7	104
384	Validating GWAS Variants from Microglial Genes Implicated in Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2017, 62, 215-221.	1.1	31
385	The Exceptional Vulnerability of Humans to Alzheimer's Disease. <i>Trends in Molecular Medicine</i> , 2017, 23, 534-545.	3.5	74
386	Chemoproteomic Profiling of Bile Acid Interacting Proteins. <i>ACS Central Science</i> , 2017, 3, 501-509.	5.3	62
387	Prion-like transmission of pathogenic protein aggregates in genetic models of neurodegenerative disease. <i>Current Opinion in Genetics and Development</i> , 2017, 44, 149-155.	1.5	13
388	Circadian Rhythms in AD Pathogenesis: a Critical Appraisal. <i>Current Sleep Medicine Reports</i> , 2017, 3, 85-92.	0.7	26
389	Alzheimer's disease in the zebrafish: where can we take it?. <i>Behavioural Pharmacology</i> , 2017, 28, 179-186.	0.8	14
390	The blood brain barrier in Alzheimer's disease. <i>Vascular Pharmacology</i> , 2017, 89, 12-18.	1.0	84
391	Presenilin-1 Targeted Morpholino Induces Cognitive Deficits, Increased Brain A β 1-42 and Decreased Synaptic Marker PSD-95 in Zebrafish Larvae. <i>Neurochemical Research</i> , 2017, 42, 2959-2967.	1.6	16
392	TRPC Channels and Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 976, 73-83.	0.8	12
393	Targeting Neural Hyperactivity as a Treatment to Stem Progression of Late-Onset Alzheimer's Disease. <i>Neurotherapeutics</i> , 2017, 14, 662-676.	2.1	77
394	The value of whole-brain CT perfusion imaging and CT angiography using a 320-slice CT scanner in the diagnosis of MCI and AD patients. <i>European Radiology</i> , 2017, 27, 4756-4766.	2.3	14
395	A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. <i>Cell</i> , 2017, 169, 1276-1290.e17.	13.5	3,282
396	PET Imaging for Early Detection of Alzheimer's Disease. <i>PET Clinics</i> , 2017, 12, 329-350.	1.5	44
397	Discovery of the first dual GSK3 β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 45701.	1.6	59
398	Early-stage reduction of the dendritic complexity in basolateral amygdala of a transgenic mouse model of Alzheimer's disease. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 679-685.	1.0	9

#	ARTICLE	IF	CITATIONS
399	Sphingosine 1-phosphate â€“ A double edged sword in the brain. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2017, 1859, 1573-1582.	1.4	61
400	Late Onset Alzheimerâ€™s Disease Risk Variants in Cognitive Decline: The PATH Through Life Study. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 423-436.	1.2	24
401	Systematic development of small molecules to inhibit specific microscopic steps of A β 242 aggregation in Alzheimerâ€™s disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E200-E208.	3.3	180
402	Young microglia restore amyloid plaque clearance of aged microglia. <i>EMBO Journal</i> , 2017, 36, 583-603.	3.5	124
403	Human umbilical cord mesenchymal stem cells transplantation improves cognitive function in Alzheimerâ€™s disease mice by decreasing oxidative stress and promoting hippocampal neurogenesis. <i>Behavioural Brain Research</i> , 2017, 320, 291-301.	1.2	105
404	Late-onset Alzheimerâ€™s disease is associated with inherent changes in bioenergetics profiles. <i>Scientific Reports</i> , 2017, 7, 14038.	1.6	96
405	Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging. <i>Scientific Reports</i> , 2017, 7, 14849.	1.6	71
406	TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 11524-11529.	3.3	328
407	Endothelial LRP1 â€“ A Potential Target for the Treatment of Alzheimerâ€™s Disease. <i>Pharmaceutical Research</i> , 2017, 34, 2637-2651.	1.7	43
408	Partial volume correction for PET quantification and its impact on brain network in Alzheimerâ€™s disease. <i>Scientific Reports</i> , 2017, 7, 13035.	1.6	37
409	Computational integration of nanoscale physical biomarkers and cognitive assessments for Alzheimerâ€™s disease diagnosis and prognosis. <i>Science Advances</i> , 2017, 3, e1700669.	4.7	18
410	Elucidation of Dietary Polyphenolics as Potential Inhibitor of Microtubule Affinity Regulating Kinase 4: In silico and In vitro Studies. <i>Scientific Reports</i> , 2017, 7, 9470.	1.6	91
411	Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β 2-Amyloid in Alzheimerâ€™s Disease Brain. <i>Bioconjugate Chemistry</i> , 2017, 28, 2627-2637.	1.8	15
412	Dual roles of A β 2 in proliferative processes in an amyloidogenic model of Alzheimerâ€™s disease. <i>Scientific Reports</i> , 2017, 7, 10085.	1.6	34
413	MEG biomarker of Alzheimer's disease: Absence of a prefrontal generator during auditory sensory gating. <i>Human Brain Mapping</i> , 2017, 38, 5180-5194.	1.9	20
414	The vascular basement membrane in the healthy and pathological brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3300-3317.	2.4	306
415	An acetylationâ€“phosphorylation switch that regulates tau aggregation propensity and function. <i>Journal of Biological Chemistry</i> , 2017, 292, 15277-15286.	1.6	100
416	Design and synthesis of new theranostic agents for near-infrared imaging of β 2-amyloid plaques and inhibition of β 2-amyloid aggregation in Alzheimer's disease. <i>Dyes and Pigments</i> , 2017, 147, 130-140.	2.0	18

#	ARTICLE	IF	CITATIONS
417	TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. <i>Cell</i> , 2017, 170, 649-663.e13.	13.5	741
418	Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1131-1136.	1.9	44
419	Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	108
420	Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4). <i>Progress in Medicinal Chemistry</i> , 2017, 56, 117-163.	4.1	19
421	Alzheimer's Disease's Current Status and Future Directions. <i>Journal of Medicinal Food</i> , 2017, 20, 1141-1151.	0.8	21
422	Glial Draper Rescues A β Toxicity in a <i>Drosophila</i> Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2017, 37, 11881-11893.	1.7	56
423	Protein homeostasis of a metastable subproteome associated with Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5703-E5711.	3.3	77
424	Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 13.	3.0	88
425	Nanobiomaterials applications in neurodegenerative diseases. <i>Journal of Biomaterials Applications</i> , 2017, 31, 953-984.	1.2	44
426	Visual system manifestations of Alzheimer's disease. <i>Acta Ophthalmologica</i> , 2017, 95, e668-e676.	0.6	48
427	Left-handed polyproline-II helix revisited: proteins causing proteopathies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017, 35, 2701-2713.	2.0	19
428	Rare Genetic Variants of the Transthyretin Gene Are Associated with Alzheimer's Disease in Han Chinese. <i>Molecular Neurobiology</i> , 2017, 54, 5192-5200.	1.9	24
429	Sleep in Alzheimer's Disease—Beyond Amyloid. <i>Neurobiology of Sleep and Circadian Rhythms</i> , 2017, 2, 4-14.	1.4	126
430	Targeting SUMO-1ylation Contrasts Synaptic Dysfunction in a Mouse Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2017, 54, 6609-6623.	1.9	26
431	Microdevice Platform for In Vitro Nervous System and Its Disease Model. <i>Bioengineering</i> , 2017, 4, 77.	1.6	15
432	Driver or Passenger: Epigenomes in Alzheimer's Disease. <i>Epigenomes</i> , 2017, 1, 5.	0.8	2
433	Involvement of the Bradykinin B1 Receptor in Microglial Activation: In Vitro and In Vivo Studies. <i>Frontiers in Endocrinology</i> , 2017, 8, 82.	1.5	28
434	Semantic Feature Training in Combination with Transcranial Direct Current Stimulation (tDCS) for Progressive Anomia. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 253.	1.0	38

#	ARTICLE	IF	CITATIONS
435	Biomarkers for Alzheimer's Disease. , 2017, , 247-277.		0
436	Citalopram Ameliorates Impairments in Spatial Memory and Synaptic Plasticity in Female 3xTgAD Mice. BioMed Research International, 2017, 2017, 1-12.	0.9	21
437	Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases. Mediators of Inflammation, 2017, 2017, 1-15.	1.4	43
438	Amyloid-Related Imaging Abnormalities in An Aged Squirrel Monkey with Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2017, 57, 519-530.	1.2	22
439	Sleep and Memory Formation in Drosophila. , 2017, , 517-527.		6
440	A Becn1 mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease. PLoS Genetics, 2017, 13, e1006962.	1.5	120
441	Associations of thyroid hormone serum levels with in-vivo Alzheimer's disease pathologies. Alzheimer's Research and Therapy, 2017, 9, 64.	3.0	35
442	Role of BACE1 in Alzheimer's synaptic function. Translational Neurodegeneration, 2017, 6, 23.	3.6	80
443	Microvascular ultrastructural changes precede cognitive impairment in the murine APPswe/PS1dE9 model of Alzheimer's disease. Angiogenesis, 2017, 20, 567-580.	3.7	40
444	Sleep, Adenosine, and Neurodegeneration. , 2017, , 111-130.		0
445	Neuroprotective effects of baicalin against cognitive impairment induced by amyloid-β in APP/PS1 mice. Oncotarget, 2017, 8, 92621-92634.	0.8	20
446	Calcium Dysregulation in Alzheimer's Disease: A Target for New Drug Development. , 2017, 7, .		78
447	A Network of Genetic Effects on Non-Demented Cognitive Aging: Alzheimer's Genetic Risk (CLU +) Tj ETQq0 0 0 rgBT /Overlock 10 T Journal of Alzheimer's Disease, 2018, 62, 887-900.	1.2	13
448	Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. Journal of Alzheimer's Disease, 2018, 62, 745-756.	1.2	45
449	MicroRNA-132 is associated with the cognition improvement following voluntary exercise in SAMP8 mice. Brain Research Bulletin, 2018, 140, 80-87.	1.4	28
450	Stress as risk factor for Alzheimer's disease. Pharmacological Research, 2018, 132, 130-134.	3.1	69
451	Age-Dependent Changes to Sphingolipid Balance in the Human Hippocampus are Gender-Specific and May Sensitize to Neurodegeneration. Journal of Alzheimer's Disease, 2018, 63, 503-514.	1.2	39
452	Evidence for Compromised Insulin Signaling and Neuronal Vulnerability in Experimental Model of Sporadic Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 8916-8935.	1.9	29

#	ARTICLE	IF	CITATIONS
453	Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. <i>Advances in Pharmacology</i> , 2018, 82, 293-323.	1.2	67
454	The Progression of Dementia and Cognitive Decline in a Dutch 2-Year Cohort Study of People with Young-Onset Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 343-351.	1.2	14
455	Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1815-1826.	1.2	11
456	Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 37-45.	1.8	29
457	High fat diet treatment impairs hippocampal long-term potentiation without alterations of the core neuropathological features of Alzheimer disease. <i>Neurobiology of Disease</i> , 2018, 113, 82-96.	2.1	34
458	Enantiomeric lignans with anti- β -amyloid aggregation activity from the twigs and leaves of <i>Pithecellobium clypearia</i> Benth. <i>Bioorganic Chemistry</i> , 2018, 77, 579-585.	2.0	13
459	How the formation of amyloid plaques and neurofibrillary tangles may be related: a mathematical modelling study. <i>Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences</i> , 2018, 474, 20170777.	1.0	18
460	Factors influencing accuracy of cortical thickness in the diagnosis of Alzheimer's disease. <i>Human Brain Mapping</i> , 2018, 39, 1500-1515.	1.9	21
461	The Role of Synapsins in Neurological Disorders. <i>Neuroscience Bulletin</i> , 2018, 34, 349-358.	1.5	72
462	Design of nonapeptide LVFFARKHH: A bifunctional agent against Cu^{2+} -mediated amyloid β -protein aggregation and cytotoxicity. <i>Journal of Molecular Recognition</i> , 2018, 31, e2697.	1.1	20
463	A Metallo-Protein Drug to Target Cu^{II} in the Context of Alzheimer's Disease. <i>Chemistry - A European Journal</i> , 2018, 24, 5095-5099.	1.7	19
464	Bexarotene Binds to the Amyloid Precursor Protein Transmembrane Domain, Alters Its α -Helical Conformation, and Inhibits β -Secretase Nonselectively in Liposomes. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1702-1713.	1.7	11
465	Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). <i>Molecular Neurodegeneration</i> , 2018, 13, 15.	4.4	124
466	The physics of polymer chain-folding. <i>Physics Reports</i> , 2018, 747, 1-50.	10.3	126
467	Conformational evolution of polymorphic amyloid assemblies. <i>Current Opinion in Structural Biology</i> , 2018, 51, 135-140.	2.6	14
468	Untangling Genetic Risk for Alzheimer's Disease. <i>Biological Psychiatry</i> , 2018, 83, 300-310.	0.7	160
469	Anesthetic Implications of Chronic Medication Use. , 2018, , 333-350.		0
470	How efficient are rodent models for Alzheimer's disease drug discovery?. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 113-115.	2.5	2

#	ARTICLE	IF	CITATIONS
471	Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. <i>Alzheimer's and Dementia</i> , 2018, 14, 205-214.	0.4	109
472	Regulation of spine structural plasticity by Arc/Arg3.1. <i>Seminars in Cell and Developmental Biology</i> , 2018, 77, 25-32.	2.3	36
473	Oxidative stress and the amyloid beta peptide in Alzheimer's disease. <i>Redox Biology</i> , 2018, 14, 450-464.	3.9	1,411
474	Cu ^{II} Binding to Various Forms of Amyloid β Peptides: Are They Friends or Foes?. <i>European Journal of Inorganic Chemistry</i> , 2018, 2018, 7-15.	1.0	33
475	Protection against β -amyloid neurotoxicity by a non-toxic endogenous N-terminal β -amyloid fragment and its active hexapeptide core sequence. <i>Journal of Neurochemistry</i> , 2018, 144, 201-217.	2.1	23
476	Chronic deep brain stimulation in an Alzheimer's disease mouse model enhances memory and reduces pathological hallmarks. <i>Brain Stimulation</i> , 2018, 11, 435-444.	0.7	49
477	Synthesis, biological evaluation and structure-activity relationship studies of hederacolchiside E and its derivatives as potential anti-Alzheimer agents. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 376-389.	2.6	12
478	Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease. <i>Neuropharmacology</i> , 2018, 136, 362-373.	2.0	90
479	The Neuroprotective Effects of Experience on Cognitive Functions: Evidence from Animal Studies on the Neurobiological Bases of Brain Reserve. <i>Neuroscience</i> , 2018, 370, 218-235.	1.1	86
480	Episodix: a serious game to detect cognitive impairment in senior adults. A psychometric study. <i>PeerJ</i> , 2018, 6, e5478.	0.9	19
481	Making the final cut: pathogenic amyloid- β peptide generation by β -secretase. <i>Cell Stress</i> , 2018, 2, 292-310.	1.4	100
482	Socially Assistive Robots Diffusion in Elderly Care: A Pre-Adoption Study through Agent-Based Modeling. , 2018, , .		1
483	Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. <i>Advanced Materials</i> , 2018, 30, e1801362.	11.1	415
484	Effective Use of Data Science Toward Early Prediction of Alzheimer's Disease. , 2018, , .		6
485	Topological Biomarker of Alzheimer's Disease. , 0, , .		1
486	Functional alterations of myeloid cells during the course of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2018, 13, 61.	4.4	44
487	RAB10: an Alzheimer's disease resilience locus and potential drug target. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 73-79.	1.3	37
488	Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer's disease. <i>International Journal of Molecular Medicine</i> , 2019, 43, 956-966.	1.8	48

#	ARTICLE	IF	CITATIONS
489	New insights into the role of TREM2 in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2018, 13, 66.	4.4	286
490	Early Changes in Hippocampal Neurogenesis Induced by Soluble A β ²¹⁻⁴² Oligomers. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2018, 12, 330-338.	0.2	0
491	The Role of KLF4 in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 325.	1.8	40
493	Biomolecular Assemblies: Moving from Observation to Predictive Design. <i>Chemical Reviews</i> , 2018, 118, 11519-11574.	23.0	71
494	Animal models of neurodegenerative diseases. <i>Nature Neuroscience</i> , 2018, 21, 1370-1379.	7.1	358
495	SAR by kinetics for drug discovery in protein misfolding diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10245-10250.	3.3	54
496	Increased Insoluble Amyloid- β ² Induces Negligible Cognitive Deficits in Old AppNL/NL Knock-In Mice. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 801-809.	1.2	8
497	Aldosterone exerts anti-inflammatory effects on LPS stimulated microglia. <i>Heliyon</i> , 2018, 4, e00826.	1.4	5
498	The Reelin Receptors Apolipoprotein E receptor 2 (ApoER2) and VLDL Receptor. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3090.	1.8	53
499	Paired Immunoglobulin-like Type 2 Receptor Alpha G78R variant alters ligand binding and confers protection to Alzheimer's disease. <i>PLoS Genetics</i> , 2018, 14, e1007427.	1.5	56
500	Impaired Spike Timing Dependent Cortico-Cortical Plasticity in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 983-991.	1.2	43
501	Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3081.	1.8	28
502	Fighting the Cause of Alzheimer's and GNE Myopathy. <i>Frontiers in Neuroscience</i> , 2018, 12, 669.	1.4	7
503	Learning to Detect Cognitive Impairment through Digital Games and Machine Learning Techniques. <i>Methods of Information in Medicine</i> , 2018, 57, 197-207.	0.7	23
504	AMPA-ergic regulation of amyloid- β ² levels in an Alzheimer's disease mouse model. <i>Molecular Neurodegeneration</i> , 2018, 13, 22.	4.4	41
505	Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	39
506	A standard model of Alzheimer's disease?. <i>Prion</i> , 2018, 12, 261-265.	0.9	20
507	Study of altered functional connectivity in individuals at risk for Alzheimer's Disease. <i>Technology and Health Care</i> , 2018, 26, 103-111.	0.5	7

#	ARTICLE	IF	CITATIONS
508	Chronic stress as a risk factor for Alzheimer's disease: Roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress. <i>Neurobiology of Stress</i> , 2018, 9, 9-21.	1.9	255
509	Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid- β^2 clearance in human astrocytes. <i>Journal of Biological Chemistry</i> , 2018, 293, 11341-11357.	1.6	49
510	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. <i>NeuroImage: Clinical</i> , 2018, 19, 406-416.	1.4	76
511	Metabolic fate of glucose in the brain of APP/PS1 transgenic mice at 10 months of age: a ^{13}C NMR metabolomic study. <i>Metabolic Brain Disease</i> , 2018, 33, 1661-1668.	1.4	19
512	Valproic acid attenuates $\text{A}\beta^{25-35}$ -induced neurotoxicity in PC12 cells through suppression of mitochondria-mediated apoptotic pathway. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 77-82.	2.5	21
513	Morphological Biomarker Differentiating MCI Converters from Nonconverters: Longitudinal Evidence Based on Hemispheric Asymmetry. <i>Behavioural Neurology</i> , 2018, 2018, 1-9.	1.1	17
514	Emotional Lability as a Unique Presenting Sign of Suspected Chronic Traumatic Encephalopathy. <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-4.	0.3	3
515	Using <i>Drosophila</i> Models of Amyloid Toxicity to Study Autophagy in the Pathogenesis of Alzheimer's Disease. <i>BioMed Research International</i> , 2018, 2018, 1-14.	0.9	15
516	Oil Palm Phenolics Inhibit the <i>In Vitro</i> Aggregation of $\text{A}\beta^{1-42}$ -Amyloid Peptide into Oligomeric Complexes. <i>International Journal of Alzheimer's Disease</i> , 2018, 2018, 1-12.	1.1	14
517	Translational opportunities for amyloid-targeting fluorophores. <i>Chemical Communications</i> , 2018, 54, 9107-9118.	2.2	27
518	Heme Oxygenase-1 Activity as a Correlate to Exercise-Mediated Amelioration of Cognitive Decline and Neuropathological Alterations in an Aging Rat Model of Dementia. <i>BioMed Research International</i> , 2018, 2018, 1-13.	0.9	24
519	Pyrazinyl ureas revisited: 1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea, a new blocker of $\text{A}\beta^2$ -induced mPTP opening for Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 268-278.	2.6	10
520	Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. <i>Journal of Experimental Medicine</i> , 2018, 215, 2235-2245.	4.2	167
521	One-step synthesized flower-like materials used for sensitively detecting amyloid precursor protein. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 6901-6909.	1.9	9
522	Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases. <i>Frontiers in Pharmacology</i> , 2018, 9, 145.	1.6	53
523	Cornel Iridoid Glycoside Inhibits Tau Hyperphosphorylation via Regulating Cross-Talk Between GSK-3 β and PP2A Signaling. <i>Frontiers in Pharmacology</i> , 2018, 9, 682.	1.6	27
524	TREM2-Dependent Effects on Microglia in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 202.	1.7	60
525	The Role of Microglia in the Spread of Tau: Relevance for Tauopathies. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 172.	1.8	92

#	ARTICLE	IF	CITATIONS
526	Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer's Disease and Reconstruction of Relevant Biological Mechanisms. <i>Scientific Reports</i> , 2018, 8, 11173.	1.6	59
527	Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. <i>Annual Review of Cell and Developmental Biology</i> , 2018, 34, 545-568.	4.0	99
528	Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 69.	3.0	22
529	Naringin Dihydrochalcone Ameliorates Cognitive Deficits and Neuropathology in APP/PS1 Transgenic Mice. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 169.	1.7	40
530	Potential Utility of Retinal Imaging for Alzheimer's Disease: A Review. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 188.	1.7	52
531	Acetylation Disfavors Tau Phase Separation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1360.	1.8	136
532	Tryptophan-Containing Dual Neuroprotective Peptides: Prolyl Endopeptidase Inhibition and <i>Caenorhabditis elegans</i> Protection from A β -Amyloid Peptide Toxicity. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1491.	1.8	11
533	Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. <i>Genome Medicine</i> , 2018, 10, 43.	3.6	62
535	Prevalence and Incidence of Statin Use and 3-Year Adherence and Discontinuation Rates Among Older Adults With Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 527-534.	0.9	11
536	PM20D1 is a quantitative trait locus associated with Alzheimer's disease. <i>Nature Medicine</i> , 2018, 24, 598-603.	15.2	73
537	Solvation-Guided Design of Fluorescent Probes for Discrimination of Amyloids. <i>Scientific Reports</i> , 2018, 8, 6950.	1.6	21
538	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. <i>Intelligence</i> , 2018, 70, 22-29.	1.6	13
539	Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. <i>Nature Reviews Immunology</i> , 2018, 18, 759-772.	10.6	394
540	Jujuboside A promotes A β clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPAR γ pathway. <i>Theranostics</i> , 2018, 8, 4262-4278.	4.6	85
541	TMEM30A is a candidate interacting partner for the A β -carboxyl-terminal fragment of amyloid- β precursor protein in endosomes. <i>PLoS ONE</i> , 2018, 13, e0200988.	1.1	12
542	Okadaic acid-induced tau hyperphosphorylation and the downregulation of Pin1 expression in primary cortical neurons. <i>Journal of Chemical Neuroanatomy</i> , 2018, 92, 41-47.	1.0	12
543	Prion-like mechanisms in Alzheimer disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 153, 303-319.	1.0	42
544	Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer's disease in the 3xTg-AD mouse model. <i>Cell Death and Disease</i> , 2018, 9, 685.	2.7	120

#	ARTICLE	IF	CITATIONS
545	Single-Exosome-Counting Immunoassays for Cancer Diagnostics. <i>Nano Letters</i> , 2018, 18, 4226-4232.	4.5	292
546	Bidirectional relationships between sleep and amyloid-beta in the hippocampus. <i>Neurobiology of Learning and Memory</i> , 2019, 160, 108-117.	1.0	19
547	PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. <i>Neuroscience Letters</i> , 2019, 691, 44-50.	1.0	85
548	Association of Environmental Features and the Risk of Alzheimer's Dementia in Older Adults: A Nationwide Longitudinal Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2828.	1.2	14
549	Comparison of Retinal Microvasculature in Patients With Alzheimer's Disease and Primary Open-Angle Glaucoma by Optical Coherence Tomography Angiography. , 2019, 60, 3447.		70
550	Chrelin in Alzheimer's disease: Pathologic roles and therapeutic implications. <i>Ageing Research Reviews</i> , 2019, 55, 100945.	5.0	34
551	Taking Neuropsychological Test to the Next Level: Commercial Virtual Reality Video Games for the Assessment of Executive Functions. <i>Lecture Notes in Computer Science</i> , 2019, , 133-149.	1.0	5
552	Human Albumin Impairs Amyloid β -peptide Fibrillation Through its C-terminus: From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 963-971.	1.9	19
553	Interplay Between Macular Retinal Changes and White Matter Integrity in Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 723-732.	1.2	11
554	Microwave-Assisted Organic Synthesis, structure-activity relationship, kinetics and molecular docking studies of non-cytotoxic benzamide derivatives as selective butyrylcholinesterase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 4030-4040.	1.4	17
555	Inhibition of Polo-like kinase 2 ameliorates pathogenesis in Alzheimer's disease model mice. <i>PLoS ONE</i> , 2019, 14, e0219691.	1.1	14
556	Phenothiazine-based theranostic compounds for in vivo near-infrared fluorescence imaging of β -amyloid plaques and inhibition of $A\beta$ aggregation. <i>Dyes and Pigments</i> , 2019, 171, 107744.	2.0	8
557	Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 181, 111550.	2.6	21
558	Promoter DNA hypermethylation - Implications for Alzheimer's disease. <i>Neuroscience Letters</i> , 2019, 711, 134403.	1.0	23
559	Consequences of Metabolic Disruption in Alzheimer's Disease Pathology. <i>Neurotherapeutics</i> , 2019, 16, 600-610.	2.1	51
560	A Machine Learning Approach to the Early Diagnosis of Alzheimer's Disease Based on an Ensemble of Classifiers. <i>Lecture Notes in Computer Science</i> , 2019, , 383-396.	1.0	6
561	Emerging Signal Regulating Potential of Genistein Against Alzheimer's Disease: A Promising Molecule of Interest. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 197.	1.8	91
562	Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2019, 39, 9645-9659.	1.7	22

#	ARTICLE	IF	CITATIONS
563	Cut microbiota mediated allostasis prevents stress-induced neuroinflammatory risk factors of Alzheimer's disease. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 168, 147-181.	0.9	21
564	Computational analysis of Alzheimer-causing mutations in amyloid precursor protein and presenilin 1. <i>Archives of Biochemistry and Biophysics</i> , 2019, 678, 108168.	1.4	13
565	Dietary Neuroketotherapeutics for Alzheimer's Disease: An Evidence Update and the Potential Role for Diet Quality. <i>Nutrients</i> , 2019, 11, 1910.	1.7	37
566	Type-2-Diabetes Alters CSF but Not Plasma Metabolomic and AD Risk Profiles in Vervet Monkeys. <i>Frontiers in Neuroscience</i> , 2019, 13, 843.	1.4	17
567	Template-Mediated Detoxification of Low-Molecular-Weight Amyloid Oligomers and Regulation of Their Nucleation Pathway. <i>ACS Applied Bio Materials</i> , 2019, 2, 5306-5312.	2.3	8
568	EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE?. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019, 6, 1-2.	1.5	6
569	The microbiome: A target for Alzheimer disease?. <i>Cell Research</i> , 2019, 29, 779-780.	5.7	32
570	Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 382-387.	1.8	34
571	A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer's disease. <i>Neuropharmacology</i> , 2019, 160, 107785.	2.0	18
572	A Fragment of S38AA is a Novel Plasma Biomarker of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1163-1174.	1.2	6
573	The Interaction Between Sleep and Metabolism in Alzheimer's Disease: Cause or Consequence of Disease?. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 258.	1.7	19
574	Risk Factors for Alzheimer's Disease: Focus on Stress. <i>Frontiers in Pharmacology</i> , 2019, 10, 976.	1.6	20
575	Dual-probe (colorimetric and fluorometric) detection of ferritin using antibody-modified gold@carbon dot nanoconjugates. <i>Mikrochimica Acta</i> , 2019, 186, 687.	2.5	15
576	Dietary Restriction and Neuroinflammation: A Potential Mechanistic Link. <i>International Journal of Molecular Sciences</i> , 2019, 20, 464.	1.8	29
577	Computing the Pathogenicity of Alzheimer's Disease Presenilin 1 Mutations. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 858-870.	2.5	19
578	KIR2DS2/KIR2DL2/HLA-C1 Haplotype Is Associated with Alzheimer's Disease: Implication for the Role of Herpesvirus Infections. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1379-1389.	1.2	36
579	An ultrasensitive electrochemical aptasensor for early diagnosis of Alzheimer's disease, using a fern leaves-like gold nanostructure. <i>Talanta</i> , 2019, 198, 510-517.	2.9	80
580	Copper-Targeting Approaches in Alzheimer's Disease: How To Improve the Fallouts Obtained from in Vitro Studies. <i>Inorganic Chemistry</i> , 2019, 58, 13509-13527.	1.9	61

#	ARTICLE	IF	CITATIONS
581	The Biosynthesis, Signaling, and Neurological Functions of Bile Acids. <i>Biomolecules</i> , 2019, 9, 232.	1.8	116
582	Early Seizure Activity Accelerates Depletion of Hippocampal Neural Stem Cells and Impairs Spatial Discrimination in an Alzheimer's Disease Model. <i>Cell Reports</i> , 2019, 27, 3741-3751.e4.	2.9	51
583	Assessing Neuroprotective Agents for A β -Induced Neurotoxicity. <i>Trends in Molecular Medicine</i> , 2019, 25, 685-695.	3.5	18
584	Benefits of curcumin in brain disorders. <i>BioFactors</i> , 2019, 45, 666-689.	2.6	117
585	Modulating Hinge Flexibility in the APP Transmembrane Domain Alters A β -Secretase Cleavage. <i>Biophysical Journal</i> , 2019, 116, 2103-2120.	0.2	34
586	Diagnosis and prognosis of Alzheimer's disease using brain morphometry and white matter connectomes. <i>NeuroImage: Clinical</i> , 2019, 23, 101859.	1.4	24
587	Comparative biophysical characterization: A screening tool for acetylcholinesterase inhibitors. <i>PLoS ONE</i> , 2019, 14, e0215291.	1.1	12
588	Dynamics of Inter-Molecular Interactions Between Single A β ²⁴² Oligomeric and Aggregate Species by High-Speed Atomic Force Microscopy. <i>Journal of Molecular Biology</i> , 2019, 431, 2687-2699.	2.0	14
589	Effects of <i>in vivo</i> conditions on amyloid aggregation. <i>Chemical Society Reviews</i> , 2019, 48, 3946-3996.	18.7	148
590	Lipid Metabolism in Late-Onset Alzheimer's Disease Differs from Patients Presenting with Other Dementia Phenotypes. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1995.	1.2	11
591	Single-cell transcriptomic analysis of Alzheimer's disease. <i>Nature</i> , 2019, 570, 332-337.	13.7	1,528
592	Endophilin 1 knockdown prevents synaptic dysfunction induced by oligomeric amyloid A β ² . <i>Molecular Medicine Reports</i> , 2019, 19, 4897-4905.	1.1	4
593	Near-Infrared Activated Black Phosphorus as a Nontoxic Photo-Oxidant for Alzheimer's Amyloid A β ² Peptide. <i>Small</i> , 2019, 15, e1901116.	5.2	66
594	Epigenetic Modifications in Alzheimer's Neuropathology and Therapeutics. <i>Frontiers in Neuroscience</i> , 2019, 13, 476.	1.4	50
595	Neurochemical Aspects of Alzheimer's Type of Dementia. , 2019, , 73-112.		1
596	Non-conventional compounds with potential therapeutic effects against Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 375-395.	1.4	12
597	Touchscreen games to detect cognitive impairment in senior adults. A user-interaction pilot study. <i>International Journal of Medical Informatics</i> , 2019, 127, 52-62.	1.6	30
598	Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1829.	1.8	43

#	ARTICLE	IF	CITATIONS
599	Rapid Dissolution of Amyloid β Fibrils by Silver Nanoplates. <i>Langmuir</i> , 2019, 35, 6962-6970.	1.6	23
600	Mitochondrial transport serves as a mitochondrial quality control strategy in axons: Implications for central nervous system disorders. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 876-886.	1.9	51
601	The Use of Pluripotent Stem Cell-Derived Organoids to Study Extracellular Matrix Development during Neural Degeneration. <i>Cells</i> , 2019, 8, 242.	1.8	14
602	Microglia-Specific Metabolic Changes in Neurodegeneration. <i>Journal of Molecular Biology</i> , 2019, 431, 1830-1842.	2.0	83
603	Curcumin-primed exosomes potentially ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT/GSK-3 β pathway. <i>Nanoscale</i> , 2019, 11, 7481-7496.	2.8	202
604	Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model. <i>Nature Communications</i> , 2019, 10, 1365.	5.8	217
605	Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 28.	3.0	27
606	Involvement of RhoA/ROCK Signaling in β -Induced Chemotaxis, Cytotoxicity and Inflammatory Response of Microglial BV2 Cells. <i>Cellular and Molecular Neurobiology</i> , 2019, 39, 637-650.	1.7	20
607	Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimer's Disease. <i>Neuroscience Bulletin</i> , 2019, 35, 934-936.	1.5	0
608	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	1.2	84
609	Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice. <i>Journal of Neuroinflammation</i> , 2019, 16, 62.	3.1	152
610	Understanding the Amyloid Hypothesis in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 493-510.	1.2	77
611	The Retina in Alzheimer's Disease: Histomorphometric Analysis of an Ophthalmologic Biomarker. , 2019, 60, 1491.		55
612	Abnormal Brain Network Connectivity in a Triple-Network Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 237-252.	1.2	37
613	Nanoparticle Assisted Regulation of Nucleation Pathway of Amyloid Tetramer and Inhibition of Their Fibrillation Kinetics. <i>ACS Applied Bio Materials</i> , 2019, 2, 2137-2142.	2.3	16
614	Important advances in Alzheimer's disease from the use of induced pluripotent stem cells. <i>Journal of Biomedical Science</i> , 2019, 26, 15.	2.6	9
615	Translational control in brain pathologies: biological significance and therapeutic opportunities. <i>Acta Neuropathologica</i> , 2019, 137, 535-555.	3.9	23
616	Aberrant Excitatory/Inhibitory Synaptic Mechanisms in Entorhinal Cortex Microcircuits During the Pathogenesis of Alzheimer's Disease. <i>Cerebral Cortex</i> , 2019, 29, 1834-1850.	1.6	90

#	ARTICLE	IF	CITATIONS
617	Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 33-38.	1.2	44
618	The Alz-tau Biomarker for Alzheimer's Disease: Study in a Caucasian Population. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1181-1186.	1.2	11
619	Neuroprotective Function of Non-Proteolytic Amyloid- β Chaperones in Alzheimer's Disease. , 0, , .		2
620	Effects of Low-carbohydrate and High-fat Diet Supplemented with Ketogenic Drink on Cognitive Function and Physical Performance in the Elderly at High Risk for Dementia. <i>Korean Journal of Community Nutrition</i> , 2019, 24, 525.	0.1	1
621	Donepezil Derivatives Targeting Amyloid- β Cascade in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019, 16, 772-800.	0.7	18
622	Oligomeric A β in the monkey brain impacts synaptic integrity and induces accelerated cortical aging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26239-26246.	3.3	67
623	Reduced Acoustic Startle Response and Prepulse Inhibition in the Tg4-42 Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2019, 3, 269-278.	1.2	9
624	Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives. <i>Scientific Reports</i> , 2019, 9, 19011.	1.6	50
625	Social Assistive Robots for Elderly Care: The New Efficiency in the Context of Triple Bottom Line and Digitization. , 2019, , .		4
626	The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 328.	1.7	34
627	Hyperinsulinemia or Insulin Resistance: What Impacts the Progression of Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2019, 72, S71-S79.	1.2	19
628	Selective memory and behavioral alterations after ambient ultrafine particulate matter exposure in aged 3xTgAD Alzheimer's disease mice. <i>Particle and Fibre Toxicology</i> , 2019, 16, 45.	2.8	32
629	Supersaturated proteins are enriched at synapses and underlie cell and tissue vulnerability in Alzheimer's disease. <i>Heliyon</i> , 2019, 5, e02589.	1.4	23
630	NVP-BEZ235 (Dactolisib) Has Protective Effects in a Transgenic Mouse Model of Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 1345.	1.6	14
631	Association between blood lead level and subsequent Alzheimer's disease mortality. <i>Environmental Epidemiology</i> , 2019, 3, e045.	1.4	12
632	Amyloid- β oligomers suppress subunit-specific glutamate receptor increase during LTP. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 797-808.	1.8	14
633	Future Therapeutic Perspectives into the Alzheimer's Disease Targeting the Oxidative Stress Hypothesis. <i>Molecules</i> , 2019, 24, 4410.	1.7	67
634	Animal Venom Peptides as a Treasure Trove for New Therapeutics Against Neurodegenerative Disorders. <i>Current Medicinal Chemistry</i> , 2019, 26, 4749-4774.	1.2	33

#	ARTICLE	IF	CITATIONS
635	The Role of APOE and TREM2 in Alzheimer's Disease"Current Understanding and Perspectives. International Journal of Molecular Sciences, 2019, 20, 81.	1.8	123
636	Diet and biomarkers of Alzheimer's disease: a systematic review and meta-analysis. Neurobiology of Aging, 2019, 76, 45-52.	1.5	79
637	Circulating antioxidants and Alzheimer disease prevention: a Mendelian randomization study. American Journal of Clinical Nutrition, 2019, 109, 90-98.	2.2	28
638	Acidifying Endolysosomes Prevented Low-Density Lipoprotein-Induced Amyloidogenesis. Journal of Alzheimer's Disease, 2019, 67, 393-410.	1.2	19
639	Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brain-derived neurotrophic factor and therapeutic implications. CNS Neuroscience and Therapeutics, 2019, 25, 303-313.	1.9	40
640	A pyrene-inhibitor fluorescent probe with large Stokes shift for the staining of A β 1-42, α -synuclein, and amylin amyloid fibrils as well as amyloid-containing Staphylococcus aureus biofilms. Analytical and Bioanalytical Chemistry, 2019, 411, 251-265.	1.9	2
641	Chronic Sleep Restriction Induces A β Accumulation by Disrupting the Balance of A β Production and Clearance in Rats. Neurochemical Research, 2019, 44, 859-873.	1.6	34
642	18F-FDG-PET Detects Drastic Changes in Brain Metabolism in the Tg4 β 42 Model of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 425.	1.7	49
643	Dendritic spines: Revisiting the physiological role. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 161-193.	2.5	165
644	Trodusquemine enhances A β 242 aggregation but suppresses its toxicity by displacing oligomers from cell membranes. Nature Communications, 2019, 10, 225.	5.8	111
645	Diabetes and Alzheimer's Disease: A Link not as Simple as it Seems. Neurochemical Research, 2019, 44, 1271-1278.	1.6	47
646	Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid- β -Induced Synaptic Dysfunction and Loss. Journal of Neuroscience, 2019, 39, 758-772.	1.7	61
647	Incidence of prescription vitamin B12 use in relation to diagnosis of Alzheimer's disease among community-dwelling persons. Zeitschrift Fur Gesundheitswissenschaften, 2019, 27, 775-779.	0.8	0
648	Spectral-Domain OCT Measurements in Alzheimer's Disease. Ophthalmology, 2019, 126, 497-510.	2.5	236
649	The interplay between aging-associated loss of protein homeostasis and extracellular vesicles in neurodegeneration. Journal of Neuroscience Research, 2020, 98, 262-283.	1.3	21
650	Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. Neuropsychopharmacology, 2020, 45, 104-120.	2.8	280
651	The TMEM106B FTL-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathologica, 2020, 139, 45-61.	3.9	51
652	Preserved Calretinin Interneurons in an App Model of Alzheimer's Disease Disrupt Hippocampal Inhibition via Upregulated P2Y1 Purinoreceptors. Cerebral Cortex, 2020, 30, 1272-1290.	1.6	16

#	ARTICLE	IF	CITATIONS
653	Dementia in China: epidemiology, clinical management, and research advances. <i>Lancet Neurology</i> , The, 2020, 19, 81-92.	4.9	412
654	The prospective role of mesenchymal stem cells exosomes on circumvallate taste buds in induced Alzheimer's disease of ovariectomized albino rats. <i>Archives of Oral Biology</i> , 2020, 110, 104596.	0.8	10
655	Structure-Activity Relationships of Radioiodinated 6,5,6-Tricyclic Compounds for the Development of Tau Imaging Probes. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 120-126.	1.3	6
656	Proteome-wide observation of the phenomenon of life on the edge of solubility. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1015-1020.	3.3	115
657	Effect of atorvastatin on A β 1-42-induced alteration of SESN2, SIRT1, LC3II and TPP1 protein expressions in neuronal cell cultures. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 424-436.	1.2	18
658	Polysaccharides from <i>Lycium barbarum</i> ameliorate amyloid pathology and cognitive functions in APP/PS1 transgenic mice. <i>International Journal of Biological Macromolecules</i> , 2020, 144, 1004-1012.	3.6	35
659	Gut Microbiota: From the Forgotten Organ to a Potential Key Player in the Pathology of Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1232-1241.	1.7	61
660	Interaction with the environment: <i>Skin.</i> , 2020, , 29-147.		1
661	Microglial Immunometabolism in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 563446.	1.8	27
662	Scope of β -Secretase (BACE1)-Targeted Therapy in Alzheimer's Disease: Emphasizing the Flavonoid Based Natural Scaffold for BACE1 Inhibition. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3510-3522.	1.7	12
663	EphA4 regulates A β production via BACE1 expression in neurons. <i>FASEB Journal</i> , 2020, 34, 16383-16396.	0.2	8
664	How Mutations Perturb β -Secretase Active Site Studied by Free Energy Simulations. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3321-3332.	1.7	14
665	Interleukin-17A: The Key Cytokine in Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 566922.	1.7	79
666	Comprehensive chemical profiling of Jia-Wei-Qi-Fu-Yin and its network pharmacology-based analysis on Alzheimer's disease. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 189, 113467.	1.4	12
667	Exploration of the Potential Role for A β in Delivery of Extracellular Copper to Ctr1. <i>Inorganic Chemistry</i> , 2020, 59, 16952-16966.	1.9	6
668	Fate and propagation of endogenously formed Tau aggregates in neuronal cells. <i>EMBO Molecular Medicine</i> , 2020, 12, e12025.	3.3	41
669	Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8948.	1.8	53
670	Gene expression of serotonergic markers in peripheral blood mononuclear cells of patients with late-onset Alzheimer's disease. <i>Heliyon</i> , 2020, 6, e04716.	1.4	4

#	ARTICLE	IF	CITATIONS
671	Genetic Variants of Lipoprotein Lipase and Regulatory Factors Associated with Alzheimer's Disease Risk. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8338.	1.8	13
672	Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer's Disease and Ischemia-Related Brain Injury. <i>Pharmaceuticals</i> , 2020, 13, 379.	1.7	54
673	Exploring the Therapeutic Potential of Protein Tyrosine Phosphatase 1B in hAPP-J20 Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2020, 40, 6100-6102.	1.7	2
674	Human Serum Albumin-Inspired Glycopeptide-Based Multifunctional Inhibitor of Amyloid- β Toxicity. <i>ACS Omega</i> , 2020, 5, 18628-18641.	1.6	6
675	Modulating disease-relevant tau oligomeric strains by small molecules. <i>Journal of Biological Chemistry</i> , 2020, 295, 14807-14825.	1.6	35
676	Plasma Tau Variants Detected by a Novel Anti-Tau Monoclonal Antibody: A Potential Biomarker for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 877-883.	1.2	3
677	DW14006 as a direct AMPK α 1 activator improves pathology of AD model mice by regulating microglial phagocytosis and neuroinflammation. <i>Brain, Behavior, and Immunity</i> , 2020, 90, 55-69.	2.0	13
678	Microglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer's Disease Genetics. <i>Trends in Neurosciences</i> , 2020, 43, 965-979.	4.2	104
679	Computational Investigation of Gantenerumab and Crenezumab Recognition of A β 2 Fibrils in Alzheimer's Disease Brain Tissue. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3233-3244.	1.7	12
680	β -Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer's disease pathology. <i>Journal of Neuroinflammation</i> , 2020, 17, 280.	3.1	117
681	Residue-based propensity of aggregation in the Tau amyloidogenic hexapeptides AcPHF6* and AcPHF6. <i>RSC Advances</i> , 2020, 10, 27331-27335.	1.7	4
682	Discovery of Diphenoxy Derivatives with Flexible Linkers as Ligands for β -Amyloid Plaques. <i>Molecular Pharmaceutics</i> , 2020, 17, 4089-4100.	2.3	3
683	Cognitive improvements in a rat model with polyunsaturated fatty acids EPA and DHA through α 7-nicotinic acetylcholine receptors. <i>Nutritional Neuroscience</i> , 2020, , 1-10.	1.5	4
684	Anticoagulants for Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1373-1382.	1.2	15
685	Amyloid Targeting α -Artificial Chaperone α Impairs Oligomer Mediated Neuronal Damage and Mitochondrial Dysfunction Associated with Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3277-3287.	1.7	14
686	Phosphodiesterase 4D Gene Modifies the Functional Network of Patients With Mild Cognitive Impairment and Alzheimer's Disease. <i>Frontiers in Genetics</i> , 2020, 11, 890.	1.1	4
687	An fMRI Feature Selection Method Based on a Minimum Spanning Tree for Identifying Patients with Autism. <i>Symmetry</i> , 2020, 12, 1995.	1.1	10
688	Longitudinal data in peripheral blood confirm that PM20D1 is a quantitative trait locus (QTL) for Alzheimer's disease and implicate its dynamic role in disease progression. <i>Clinical Epigenetics</i> , 2020, 12, 189.	1.8	21

#	ARTICLE	IF	CITATIONS
689	Identification of Structural Calcium Binding Sites in Membrane-Bound Presenilin 1 and 2. <i>Journal of Physical Chemistry B</i> , 2020, 124, 4697-4711.	1.2	6
690	Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline. <i>PLoS ONE</i> , 2020, 15, e0232785.	1.1	31
691	Insulin resistance and Alzheimer's disease. , 2020, , 249-292.		1
692	Longitudinal survival analysis and two-group comparison for predicting the progression of mild cognitive impairment to Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2020, 341, 108698.	1.3	9
693	Rational design of a conformation-specific antibody for the quantification of A β oligomers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 13509-13518.	3.3	61
694	Plasma Clusterin as a Potential Link Between Diabetes and Alzheimer Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3058-3068.	1.8	19
695	A Cell- and Tissue-Specific Weakness of the Protein Homeostasis System Underlies Brain Vulnerability to Protein Aggregation. <i>IScience</i> , 2020, 23, 100934.	1.9	9
696	The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2108.	1.8	45
697	Early Diagnosis of Alzheimer's Disease in Blood Using a Disposable Electrochemical Microfluidic Platform. <i>ACS Sensors</i> , 2020, 5, 1010-1019.	4.0	40
698	Modeling and Targeting Alzheimer's Disease With Organoids. <i>Frontiers in Pharmacology</i> , 2020, 11, 396.	1.6	71
699	Effects of physical and social environments on the risk of dementia among Taiwanese older adults: a population-based case-control study. <i>BMC Geriatrics</i> , 2020, 20, 226.	1.1	16
700	Inhibition of mTORC1 improves STZ-induced AD-like impairments in mice. <i>Brain Research Bulletin</i> , 2020, 162, 166-179.	1.4	7
701	Association of APOE With Primary Open-Angle Glaucoma Suggests a Protective Effect for APOE ϵ 4. , 2020, 61, 3.		23
702	Microglia heterogeneity and neurodegeneration: The emerging paradigm of the role of immunity in Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2020, 341, 577185.	1.1	58
703	Evodiamine derivatives improve cognitive abilities in APP ^{swe} /PS1 ^{E9} transgenic mouse models of Alzheimer's disease. <i>Animal Models and Experimental Medicine</i> , 2020, 3, 193-199.	1.3	9
704	Pathogenic A β generation in familial Alzheimer's disease: novel mechanistic insights and therapeutic implications. <i>Current Opinion in Neurobiology</i> , 2020, 61, 73-81.	2.0	22
705	Novel presenilin 1 and 2 double knock-out cell line for in vitro validation of PSEN1 and PSEN2 mutations. <i>Neurobiology of Disease</i> , 2020, 138, 104785.	2.1	14
707	Nrf2 activation through the PI3K/GSK-3 axis protects neuronal cells from A β -mediated oxidative and metabolic damage. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 13.	3.0	42

#	ARTICLE	IF	CITATIONS
708	Reduction of Tet2 exacerbates early stage Alzheimer's pathology and cognitive impairments in 2xTg-AD mice. <i>Human Molecular Genetics</i> , 2020, 29, 1833-1852.	1.4	16
709	Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. <i>European Journal of Medicinal Chemistry</i> , 2020, 190, 112090.	2.6	15
710	Orexin-A aggravates cytotoxicity and mitochondrial impairment in SH-SY5Y cells transfected with APP ^{swe} via p38 MAPK pathway. <i>Annals of Translational Medicine</i> , 2020, 8, 5-5.	0.7	9
711	The Amyloid-beta rich CNS environment alters myeloid cell functionality independent of their origin. <i>Scientific Reports</i> , 2020, 10, 7152.	1.6	3
712	5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 844-855.	2.0	34
713	Effects of lycopene on vascular remodeling through the LXR-PI3K-AKT signaling pathway in APP/PS1 mice. <i>Biochemical and Biophysical Research Communications</i> , 2020, 526, 699-705.	1.0	8
714	Transcriptome Profile of Nicotinic Receptor-Linked Sensitization of Beta Amyloid Neurotoxicity. <i>Scientific Reports</i> , 2020, 10, 5696.	1.6	5
715	Proteomics Time-Course Study of App Knock-In Mice Reveals Novel Presymptomatic A β ⁴² -Induced Pathways to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 321-335.	1.2	9
716	PLGA Microspheres with Alginate-Coated Large Pores for the Formulation of an Injectable Depot of Donepezil Hydrochloride. <i>Pharmaceutics</i> , 2020, 12, 311.	2.0	14
717	Hippocampal Deficits in Amyloid- β -Related Rodent Models of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 266.	1.4	44
718	Circadian and sleep dysfunction in Alzheimer's disease. <i>Ageing Research Reviews</i> , 2020, 60, 101046.	5.0	99
719	Identification of calcium and integrin-binding protein 1 as a novel regulator of production of amyloid β peptide using CRISPR/Cas9-based screening system. <i>FASEB Journal</i> , 2020, 34, 7661-7674.	0.2	14
720	Effects of short- and long-term neurostimulation (tDCS) on Alzheimer's disease patients: two randomized studies. <i>Ageing Clinical and Experimental Research</i> , 2021, 33, 383-390.	1.4	35
721	β -Secretase-cleaved Tau stimulates A β production via upregulating STAT1-BACE1 signaling in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 586-603.	4.1	54
722	Overexpression of protein kinase M $\bar{1}$ in the hippocampus mitigates Alzheimer's disease-related cognitive deficit in rats. <i>Brain Research Bulletin</i> , 2021, 166, 64-72.	1.4	5
723	Smart conversational agents for the detection of neuropsychiatric disorders: A systematic review. <i>Journal of Biomedical Informatics</i> , 2021, 113, 103632.	2.5	17
724	Oxidative Damage and Antioxidant Response in Frontal Cortex of Demented and Nondemented Individuals with Alzheimer's Neuropathology. <i>Journal of Neuroscience</i> , 2021, 41, 538-554.	1.7	41
725	Tuning the activity of iminosugars: novel <i>N</i> -alkylated deoxynojirimycin derivatives as strong BuChE inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 138-146.	2.5	8

#	ARTICLE	IF	CITATIONS
726	Protein Interaction Network Biology in Neuroscience. <i>Proteomics</i> , 2021, 21, e1900311.	1.3	13
727	Pimavanserin, a 5HT _{2A} receptor inverse agonist, rapidly suppresses A β production and related pathology in a mouse model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2021, 156, 658-673.	2.1	13
728	Computational prediction and molecular mechanism of β -secretase modulators. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 157, 105626.	1.9	6
729	Early Mitochondrial Fragmentation and Dysfunction in a Drosophila Model for Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2021, 58, 143-155.	1.9	16
730	Nanotechnology in neurosurgery: a systematic review. <i>Child's Nervous System</i> , 2021, 37, 1045-1054.	0.6	4
731	Decreased Orexin Receptor 1 mRNA Expression in the Locus Coeruleus in Both Tau Transgenic rTg4510 and Tau Knockout Mice and Accompanying Ascending Arousal System Tau Invasion in rTg4510. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 693-708.	1.2	7
733	Therapeutic potential of dental pulp stem cell transplantation in a rat model of Alzheimer's disease. <i>Neural Regeneration Research</i> , 2021, 16, 893.	1.6	17
734	The application of optical coherence tomography angiography in Alzheimer's disease: A systematic review. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12149.	1.2	23
735	The role of type 2 Diabetes mellitus as a risk factor for Alzheimer's and Parkinson's diseases. <i>Research, Society and Development</i> , 2021, 10, e23410111673.	0.0	3
736	<i>Galanthus nivalis</i> L. (snowdrop)., 2021, , 301-315.		0
737	Determination of plasma β -amyloids by rolling circle amplification chemiluminescent immunoassay for noninvasive diagnosis of Alzheimer's disease. <i>Mikrochimica Acta</i> , 2021, 188, 24.	2.5	3
738	Polyphenols attenuate mitochondrial dysfunction induced by amyloid peptides. , 2021, , 317-337.		0
739	Early β adrenoceptor dependent time window for fear memory persistence in APP ^{swe} /PS1 ^{dE9} mice. <i>Scientific Reports</i> , 2021, 11, 870.	1.6	3
740	Oral administration of D-galactose increases brain tricarboxylic acid cycle enzymes activities in Wistar rats. <i>Metabolic Brain Disease</i> , 2021, 36, 1057-1067.	1.4	4
741	Trough Melatonin Levels Differ between Early and Late Phases of Alzheimer Disease. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 135-144.	0.9	5
742	Isoliquiritigenin Confers Neuroprotection and Alleviates Amyloid- β ₂₄₂ -Induced Neuroinflammation in Microglia by Regulating the Nrf2/NF- κ B Signaling. <i>Frontiers in Neuroscience</i> , 2021, 15, 638772.	1.4	22
743	Structural and Functional Dysbiosis of Fecal Microbiota in Chinese Patients With Alzheimer's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 634069.	1.8	91
744	TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	72

#	ARTICLE	IF	CITATIONS
745	Naringin ameliorates memory deficits and exerts neuroprotective effects in a mouse model of Alzheimer's disease by regulating multiple metabolic pathways. <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	26
746	The AD tau core spontaneously self-assembles and recruits full-length tau to filaments. <i>Cell Reports</i> , 2021, 34, 108843.	2.9	30
747	The Latest Research on RT-QuIC Assaysâ€”A Literature Review. <i>Pathogens</i> , 2021, 10, 305.	1.2	16
748	Complement cascade functions during brain development and neurodegeneration. <i>FEBS Journal</i> , 2022, 289, 2085-2109.	2.2	19
749	Synthesis and bio-evaluation of new multifunctional methylindolinone-1,2,3-triazole hybrids as anti-Alzheimer's agents. <i>Journal of Molecular Structure</i> , 2021, 1229, 129828.	1.8	24
750	Novel Botanical Therapeutic NB-02 Effectively Treats Alzheimerâ€™s Neuropathophysiology in an APP/PS1 Mouse Model. <i>ENeuro</i> , 2021, 8, ENEURO.0389-20.2021.	0.9	4
751	Netrin-1 receptor UNC5C cleavage by active Î³-secretase enhances neurodegeneration, promoting Alzheimerâ€™s disease pathologies. <i>Science Advances</i> , 2021, 7, .	4.7	22
752	Adenosine monophosphate activated protein kinase (AMPK) is essential for the memory improving effect of adiponectin. <i>Neuroscience Letters</i> , 2021, 749, 135721.	1.0	5
753	Examining the effects of ovarian hormone loss and diet-induced obesity on Alzheimerâ€™s disease markers of amyloid-Î² production and degradation. <i>Journal of Neurophysiology</i> , 2021, 125, 1068-1078.	0.9	3
754	Alzheimerâ€™s Diseaseâ€™ Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4805.	1.8	13
755	SIRT1-Dependent Upregulation of BDNF in Human Microglia Challenged with AÎ²: An Early but Transient Response Rescued by Melatonin. <i>Biomedicines</i> , 2021, 9, 466.	1.4	16
756	Exercise and estrogen: common pathways in Alzheimer's disease pathology. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E164-E168.	1.8	16
757	Interacting Models of Amyloid-Î² and Tau Proteins: An Approach to Identify Drug Targets in Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 405-411.	1.2	2
758	Alzheimer disease. <i>Nature Reviews Disease Primers</i> , 2021, 7, 33.	18.1	784
759	Nanomedicine against Alzheimerâ€™s and Parkinsonâ€™s Disease. <i>Current Pharmaceutical Design</i> , 2021, 27, 1507-1545.	0.9	7
760	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. <i>Psychological Science</i> , 2021, 32, 849-860.	1.8	8
761	Tau-Targeted Multifunctional Nanoinhibitor for Alzheimerâ€™s Disease. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 23328-23338.	4.0	24
762	Novel Alzheimerâ€™s disease risk variants identified based on whole-genome sequencing of APOE Î¼4 carriers. <i>Translational Psychiatry</i> , 2021, 11, 296.	2.4	13

#	ARTICLE	IF	CITATIONS
763	Bacterial sepsis increases hippocampal fibrillar amyloid plaque load and neuroinflammation in a mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2021, 152, 105292.	2.1	21
764	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. <i>Alzheimer's and Dementia</i> , 2022, 18, 178-190.	0.4	5
765	Znaczenie kwasu dokozaheksaenowego (DHA) w prewencji zaburzeń, funkcji poznawczych u osób starszych. <i>Postępy Higieny i Medycyny Doswiadczalnej</i> , 2021, 75, 345-361.	0.1	0
766	Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer's disease. <i>Japanese Journal of Radiology</i> , 2021, 39, 984-993.	1.0	4
767	Roles and Mechanisms of Gut Microbiota in Patients With Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 650047.	1.7	70
768	Tacrolimus Protects against Age-Associated Microstructural Changes in the Beagle Brain. <i>Journal of Neuroscience</i> , 2021, 41, 5124-5133.	1.7	13
769	Therapeutic efficacy of novel memantine nitrate MN-08 in animal models of Alzheimer's disease. <i>Aging Cell</i> , 2021, 20, e13371.	3.0	11
770	Understanding familial Alzheimer's disease: The fitzroy mechanism of β -secretase. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2022, 12, e1556.	6.2	8
771	The Effect of Periodontitis on Dementia and Cognitive Impairment: A Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6823.	1.2	24
772	Chronic stress and Alzheimer's disease: the interplay between the hypothalamic-pituitary-adrenal axis, genetics and microglia. <i>Biological Reviews</i> , 2021, 96, 2209-2228.	4.7	37
773	Milrinone Ameliorates the Neuroinflammation and Memory Function of Alzheimer's Disease in an APP/PS1 Mouse Model. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2129-2139.	1.0	3
774	Therapeutic Potential of Phytoconstituents in Management of Alzheimer's Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-19.	0.5	41
776	Activated microglia mitigate $A\beta$ -associated tau seeding and spreading. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	94
777	The Unfolded Protein Response in Immune Cells as an Emerging Regulator of Neuroinflammation. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 682633.	1.7	23
778	Alzheimer's classification using dynamic ensemble of classifiers selection algorithms: A performance analysis. <i>Biomedical Signal Processing and Control</i> , 2021, 68, 102729.	3.5	8
779	Decreased Glucose Metabolism and Glutamine Synthesis in the Retina of a Transgenic Mouse Model of Alzheimer's Disease. <i>Cellular and Molecular Neurobiology</i> , 2021, , 1.	1.7	4
780	Hypothesis and Theory: Characterizing Abnormalities of Energy Metabolism Using a Cellular Platform as a Personalized Medicine Approach for Alzheimer's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 697578.	1.8	4
781	Gut inflammation triggers C/EBP β -dependent gut-to-brain propagation of $A\beta$ and Tau fibrils in Alzheimer's disease. <i>EMBO Journal</i> , 2021, 40, e106320.	3.5	54

#	ARTICLE	IF	CITATIONS
782	Clinicopathological correlations and cholinesterase expression in early-onset familial Alzheimer's disease with the presenilin 1 mutation, Leu235Pro. <i>Neurobiology of Aging</i> , 2021, 103, 31-41.	1.5	2
784	Tetrahydrocurcumin ameliorates Alzheimer's pathological phenotypes by inhibition of microglial cell cycle arrest and apoptosis via Ras/ERK signaling. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111651.	2.5	22
785	Multiplex Mass Spectrometry Analysis of Amyloid Proteins in Human Plasma for Alzheimer's Disease Diagnosis. <i>Journal of Proteome Research</i> , 2021, 20, 4106-4112.	1.8	6
786	Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8208.	1.8	62
787	Vascular contributions to cognitive impairment and dementia: the emerging role of 20-HETE. <i>Clinical Science</i> , 2021, 135, 1929-1944.	1.8	11
788	Perceptions of Research Participation among a Sample of Florida Residents Aged 50 and Over Reporting Dementia. <i>Ageing International</i> , 2023, 48, 95-107.	0.6	4
789	A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1537-1552.	1.2	38
790	Advances in Genetic and Molecular Understanding of Alzheimer's Disease. <i>Genes</i> , 2021, 12, 1247.	1.0	9
791	Effect of pyrrolo[3,4-d]pyridazinone derivatives in neuroinflammation induced by preincubation with lipopolysaccharide or coculturing with microglia-like cells. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111878.	2.5	4
792	Lipid Rafts and Development of Alzheimer's Disease. , 0, , .		3
793	A Comprehensive Insight into the Mechanisms of Dopamine in Disrupting A β 2 Protofibrils and Inhibiting A β 2 Aggregation. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4007-4019.	1.7	28
794	Sex-Specific Cross Tissue Meta-Analysis Identifies Immune Dysregulation in Women With Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 735611.	1.7	23
795	The NLRP3 Inflammasome in the Pathogenesis and Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 579-598.	1.2	7
796	Microfluidic Platforms to Unravel Mysteries of Alzheimer's Disease: How Far Have We Come?. <i>Life</i> , 2021, 11, 1022.	1.1	7
797	Multimomics Identification of Potential Targets for Alzheimer Disease and Antrocin as a Therapeutic Candidate. <i>Pharmaceutics</i> , 2021, 13, 1555.	2.0	22
798	The potential roles of genetic factors in predicting ageing-related cognitive change and Alzheimer's disease. <i>Ageing Research Reviews</i> , 2021, 70, 101402.	5.0	9
799	Computational Interspecies Translation Between Alzheimer's Disease Mouse Models and Human Subjects Identifies Innate Immune Complement, TYROBP, and TAM Receptor Agonist Signatures, Distinct From Influences of Aging. <i>Frontiers in Neuroscience</i> , 2021, 15, 727784.	1.4	4
800	Melatonin protects against methamphetamine-induced Alzheimer's disease-like pathological changes in rat hippocampus. <i>Neurochemistry International</i> , 2021, 148, 105121.	1.9	11

#	ARTICLE	IF	CITATIONS
801	The expanding amyloid family: Structure, stability, function, and pathogenesis. <i>Cell</i> , 2021, 184, 4857-4873.	13.5	166
802	Distinguishing Amyloid β -Protein in a Mouse Model of Alzheimer's Disease by Label-Free Vibrational Imaging. <i>Biosensors</i> , 2021, 11, 365.	2.3	6
803	Current druggable targets for therapeutic control of Alzheimer's disease. <i>Contemporary Clinical Trials</i> , 2021, 109, 106549.	0.8	21
804	Cross-sectional associations of tau protein biomarkers with semantic and episodic memory in older adults without dementia: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2021, 71, 101449.	5.0	6
805	Sex differences in Alzheimer's disease: do differences in tau explain the verbal memory gap?. <i>Neurobiology of Aging</i> , 2021, 107, 70-77.	1.5	17
806	The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. <i>Free Radical Biology and Medicine</i> , 2021, 176, 16-33.	1.3	53
807	Flow Cytometric Evaluation of Crude Synaptosome Preparation as a Way to Study Synaptic Alteration in Neurodegenerative Diseases. <i>Neuromethods</i> , 2018, 141, 297-310.	0.2	5
808	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer's disease. , 2020, , 469-504.		5
809	Functional neuroanatomy and disorders of cognition. , 2020, , 21-47.		1
810	SEQUIN Multiscale Imaging of Mammalian Central Synapses Reveals Loss of Synaptic Connectivity Resulting from Diffuse Traumatic Brain Injury. <i>Neuron</i> , 2020, 107, 257-273.e5.	3.8	30
811	Retinal Microvascular Alterations as the Biomarkers for Alzheimer Disease: Are We There Yet?. <i>Journal of Neuro-Ophthalmology</i> , 2021, 41, 251-260.	0.4	7
816	Detecting Apoptosis as a Clinical Endpoint for Proof of a Clinical Principle. <i>Ophthalmologica</i> , 2021, 244, 408-417.	1.0	5
817	Brain-specific repression of AMPK β 1 alleviates pathophysiology in Alzheimer's model mice. <i>Journal of Clinical Investigation</i> , 2020, 130, 3511-3527.	3.9	46
818	Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. <i>Journal of Clinical Investigation</i> , 2020, 130, 4954-4968.	3.9	139
819	Thinking laterally about neurodegenerative proteinopathies. <i>Journal of Clinical Investigation</i> , 2013, 123, 1847-1855.	3.9	98
820	Development of AD-Like Pathology in Skeletal Muscle. <i>Journal of Parkinson's Disease and Alzheimer's Disease</i> , 2019, 6, 1-10.	1.5	6
821	Resveratrol Inhibits β -Amyloid-Induced Neuronal Apoptosis through Regulation of SIRT1-ROCK1 Signaling Pathway. <i>PLoS ONE</i> , 2013, 8, e59888.	1.1	130
822	Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer's Disease Using Metabolomics. <i>PLoS ONE</i> , 2013, 8, e63644.	1.1	344

#	ARTICLE	IF	CITATIONS
823	Quantitative Label-Free Proteomics for Discovery of Biomarkers in Cerebrospinal Fluid: Assessment of Technical and Inter-Individual Variation. PLoS ONE, 2013, 8, e64314.	1.1	47
824	Extremely Low-Frequency Magnetic Exposure Appears to Have No Effect on Pathogenesis of Alzheimer's Disease in Aluminum-Overloaded Rat. PLoS ONE, 2013, 8, e71087.	1.1	9
825	Impairments in Neurogenesis Are Not Tightly Linked to Depressive Behavior in a Transgenic Mouse Model of Alzheimer's Disease. PLoS ONE, 2013, 8, e79651.	1.1	17
826	The Anti-Tumor Histone Deacetylase Inhibitor SAHA and the Natural Flavonoid Curcumin Exhibit Synergistic Neuroprotection against Amyloid-Beta Toxicity. PLoS ONE, 2014, 9, e85570.	1.1	35
827	Diurnal Patterns of Soluble Amyloid Precursor Protein Metabolites in the Human Central Nervous System. PLoS ONE, 2014, 9, e89998.	1.1	44
828	A Novel Approach to Delayed-Start Analyses for Demonstrating Disease-Modifying Effects in Alzheimer's Disease. PLoS ONE, 2015, 10, e0119632.	1.1	32
829	Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid- β or Pathologic Phenotype. PLoS ONE, 2016, 11, e0159119.	1.1	9
830	MRI-assessed atrophy subtypes in Alzheimer's disease and the cognitive reserve hypothesis. PLoS ONE, 2017, 12, e0186595.	1.1	51
831	The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer's Disease-related Pathogenesis. , 2020, 11, 705.		38
832	APP Overexpression Causes A β -Independent Neuronal Death through Intrinsic Apoptosis Pathway. ENeuro, 2016, 3, ENEURO.0150-16.2016.	0.9	29
833	Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Rescue Memory Defects in <i>Drosophila</i> -Expressing Alzheimer's Disease-Related Transgenes Independently of the Canonical Renin Angiotensin System. ENeuro, 2020, 7, ENEURO.0235-20.2020.	0.9	15
834	Alzheimer's disease: amyloid-based pathogenesis and potential therapies. Cell Stress, 2018, 2, 150-161.	1.4	27
835	The combined risk effect among BIN1, CLU, and APOE genes in Alzheimer's disease. Genetics and Molecular Biology, 2020, 43, e20180320.	0.6	9
836	Opportunities in rehabilitation research. Journal of Rehabilitation Research and Development, 2013, 50, vii-xxxii.	1.6	7
837	Recent Developments in Diffusion Tensor Imaging of Brain. Radiology - Open Journal, 2016, 1, 1-12.	0.1	7
838	A β Plaques. Free Neuropathology, 2020, 1, .	2.4	21
840	Diagnostic performance of new and classic CSF biomarkers in age-related dementias. Aging, 2019, 11, 2420-2429.	1.4	20
841	TREM2 ameliorates neuroinflammatory response and cognitive impairment via PI3K/AKT/FoxO3a signaling pathway in Alzheimer's disease mice. Aging, 2020, 12, 20862-20879.	1.4	72

#	ARTICLE	IF	CITATIONS
842	Synthetic A β peptides acquire prion-like properties in the brain. <i>Oncotarget</i> , 2015, 6, 642-650.	0.8	2
843	APO ϵ 2 and education in cognitively normal older subjects with high levels of AD pathology at autopsy: findings from the Nun Study. <i>Oncotarget</i> , 2015, 6, 14082-14091.	0.8	11
844	MS4A6A genotypes are associated with the atrophy rates of Alzheimer's disease related brain structures. <i>Oncotarget</i> , 2016, 7, 58779-58788.	0.8	25
845	The impact of GAB2 genetic variations on cerebrospinal fluid markers in Alzheimer's disease. <i>Annals of Translational Medicine</i> , 2018, 6, 171-171.	0.7	7
846	Tranexamic Acid Improves Memory and Learning Abilities in Aging Mice. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 653-663.	1.5	4
847	Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2015, 22, 3169-3184.	1.2	61
848	Molecular Links Between Alzheimer's Disease and Gastrointestinal Microbiota: Emphasis on <i>Helicobacter pylori</i> Infection Involvement. <i>Current Molecular Medicine</i> , 2019, 20, 3-12.	0.6	10
849	Amyloid- β in the Cerebrospinal Fluid of APP Transgenic Mice Does not Show Prion-like Properties. <i>Current Alzheimer Research</i> , 2015, 12, 886-891.	0.7	3
850	ACAT1 as a Therapeutic Target and its Genetic Relationship with Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019, 16, 699-709.	0.7	5
851	Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2014, 12, 2-36.	1.4	163
852	Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, α -Synuclein Synthesis, Interleukin-1β Release, and Cholinergic Action.. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2013, 12, 117-128.	1.1	23
853	A Personalized Voice-Based Diet Assistant for Caregivers of Alzheimer Disease and Related Dementias: System Development and Validation. <i>Journal of Medical Internet Research</i> , 2020, 22, e19897.	2.1	25
854	Reduced Sulfotransferase SULT2A1 Activity in Patients With Alzheimer's Disease. <i>Physiological Research</i> , 2015, 64, S265-S273.	0.4	13
855	Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6906.	1.8	14
856	Type 2 Diabetes and Mild Cognitive Impairment*. <i>Progress in Biochemistry and Biophysics</i> , 2012, 39, 791-795.	0.3	4
857	Endogenous and Exogenous Factors in Hyperphosphorylation of Tau in Alzheimer's Disease*. <i>Progress in Biochemistry and Biophysics</i> , 2012, 39, 778-784.	0.3	8
858	Body fluid biomarkers in Alzheimer's disease. <i>Annals of Translational Medicine</i> , 2015, 3, 70.	0.7	17
859	Protective effect of tetrahydroxy stilbene glucoside on learning and memory by regulating synaptic plasticity. <i>Neural Regeneration Research</i> , 2016, 11, 1480.	1.6	13

#	ARTICLE	IF	CITATIONS
860	Knowledge domain and emerging trends in Alzheimer's disease: a scientometric review based on CiteSpace analysis. <i>Neural Regeneration Research</i> , 2019, 14, 1643.	1.6	102
861	Pin1 Protects Against Alzheimer's Disease: One Goal, Multiple Mechanisms. , 0, , .		2
862	Fibrillar A β 2 triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. <i>ELife</i> , 2020, 9, .	2.8	80
863	The acceptability of TV-based game platforms as an instrument to support the cognitive evaluation of senior adults at home. <i>PeerJ</i> , 2017, 5, e2845.	0.9	12
864	Leukotriene Receptor Antagonist Use and Dementia Risk in Patients With Asthma: A Retrospective Cohort Study. <i>In Vivo</i> , 2021, 35, 3297-3303.	0.6	5
865	Aged Brains Express Less Melanocortin Receptors, Which Correlates with Age-Related Decline of Cognitive Functions. <i>Molecules</i> , 2021, 26, 6266.	1.7	8
866	An Overview of the Involvement of D-Serine in Cognitive Impairment in Normal Aging and Dementia. <i>Frontiers in Psychiatry</i> , 2021, 12, 754032.	1.3	17
867	Thunbergia laurifolia Leaf Extract Inhibits Glutamate-Induced Neurotoxicity and Cell Death through Mitophagy Signaling. <i>Antioxidants</i> , 2021, 10, 1678.	2.2	7
868	Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 738971.	1.7	16
869	Genetics of Alzheimer Disease. , 2014, , .		0
870	Stem Cell Therapy for Neurological Disorders: From Bench to Bedside. , 2014, , 41-70.		0
871	Proteostasis and Secondary Proteinopathy in Alzheimer's Disease. , 2014, 04, .		0
872	A New Public Health Paradigm for Alzheimer's Disease Research. <i>SOJ Neurology</i> , 2015, 2, 01-07.	0.1	4
878	A Comparative Study of [F-18] Florbetaben (FBB) PET Imaging, Pathology, and Cognition between Normal and Alzheimer Transgenic Mice. <i>Biomedical Science Letters</i> , 2019, 25, 7-14.	0.0	1
879	Development of Artificial Catalysts that Selectively Photooxygenate Pathogenic Amyloid. Yuki Gosei <i>Kagaku Kyokaiishi/Journal of Synthetic Organic Chemistry</i> , 2019, 77, 246-253.	0.0	0
884	Review on Modelling Aspect of Ryanodine Receptor in CA1 Neuron. <i>International Journal of Engineering Research & Technology</i> , 2020, V9, .	0.2	0
885	Distinct A β 2 pathology in the olfactory bulb and olfactory deficits in a mouse model of A β 2 and τ syn co-pathology. <i>Brain Pathology</i> , 2021, , e13032.	2.1	3
886	Alzheimer's disease: Causes, treatment & basic science review. <i>IP International Journal of Comprehensive and Advanced Pharmacology</i> , 2021, 6, 108-116.	0.1	0

#	ARTICLE	IF	CITATIONS
887	Amyloid beta 1 β -42-induced animal model of dementia. , 2020, , 865-880.		1
888	Block copolymers in Alzheimer's disease therapy: A perceptive to revolutionize biomaterials. Journal of Controlled Release, 2021, 340, 271-281.	4.8	17
890	Association between Sleep, Alzheimer β ™s, and Parkinson β ™s Disease. Biology, 2021, 10, 1127.	1.3	13
891	Epidemiology and Risk Factors of Alzheimer β ™s disease in Iran: A Systematic Review. Iranian Journal of Public Health, 0, , .	0.3	6
894	Beta-amyloid toxicity modifier genes and the risk of Alzheimer's disease. American Journal of Neurodegenerative Disease, 2012, 1, 191-8.	0.1	18
895	Cerebral amyloid angiopathy in an aged sooty mangabey (Cerrocebus atys). Comparative Medicine, 2013, 63, 515-20.	0.4	4
896	Role of endolysosomes and cholesterol in the pathogenesis of Alzheimer's disease: Insights into why statins might not provide clinical benefit. Austin Journal of Pharmacology and Therapeutics, 2014, 2, .	0.0	1
897	Screening of APP interaction proteins by DUALmembrane yeast two-hybrid system. International Journal of Clinical and Experimental Pathology, 2015, 8, 2802-8.	0.5	5
898	A hybrid manifold learning algorithm for the diagnosis and prognostication of Alzheimer's disease. AMIA ... Annual Symposium proceedings, 2015, 2015, 475-83.	0.2	2
901	Stepping back to move forward: a current review of iPSCs in the fight against Alzheimer's disease. American Journal of Stem Cells, 2016, 5, 99-106.	0.4	6
903	Taming Alzheimer's disease: New perspectives, newer horizons. Iranian Journal of Neurology, 2017, 16, 146-155.	0.5	4
904	Amyloid beta accumulation in HIV-1 infected brain: the role of altered cholesterol homeostasis. Clinical Research in HIV/AIDS, 2014, 1, .	0.0	0
905	Epidemiology and Risk Factors of Alzheimer's Disease in Iran: A Systematic Review. Iranian Journal of Public Health, 2019, 48, 2133-2139.	0.3	5
906	OGDHL ameliorates cognitive impairment and Alzheimer's disease-like pathology via activating Wnt/ β -catenin signaling in Alzheimer's disease mice. Behavioural Brain Research, 2022, 418, 113673.	1.2	6
907	Roles of eukaryotic elongation factor 2 kinase (eEF2K) in neuronal plasticity, cognition, and Alzheimer disease. Journal of Neurochemistry, 2023, 166, 47-57.	2.1	12
908	Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer β ™s disease. Journal of Neuroinflammation, 2021, 18, 273.	3.1	2
909	BACE1: A Key Regulator in Alzheimer β ™s Disease Progression and Current Development of its Inhibitors. Current Neuropharmacology, 2022, 20, 1174-1193.	1.4	12
910	Mechanistic insight into the role of metformin in Alzheimer's disease. Life Sciences, 2022, 291, 120299.	2.0	19

#	ARTICLE	IF	CITATIONS
911	Patchouli alcohol as a selective estrogen receptor $\hat{1}^2$ agonist ameliorates AD-like pathology of APP/PS1 model mice. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 2226-2241.	2.8	8
912	Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise. <i>FEBS Journal</i> , 2023, 290, 1420-1453.	2.2	61
914	Profiling the oral microbiomes in patients with Alzheimer's disease. <i>Oral Diseases</i> , 2023, 29, 1341-1355.	1.5	18
915	Soluble TREM2: Innocent bystander or active player in neurological diseases?. <i>Neurobiology of Disease</i> , 2022, 165, 105630.	2.1	41
916	Synthesis of carbon quantum dots for application of alleviating amyloid- $\hat{1}^2$ mediated neurotoxicity. <i>Colloids and Surfaces B: Biointerfaces</i> , 2022, 212, 112373.	2.5	20
917	Role of Phenolic Compounds in Human Disease: Current Knowledge and Future Prospects. <i>Molecules</i> , 2022, 27, 233.	1.7	256
918	Site Readiness Framework to Improve Health System Preparedness for a Potential New Alzheimer's Disease Treatment Paradigm. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, , 1.	1.5	0
921	Differential gene expression by RNA-seq during Alzheimer's disease-like progression in the <i>Drosophila melanogaster</i> model. <i>Neuroscience Research</i> , 2022, 180, 1-12.	1.0	3
922	A Night-Time Monitoring System (eNightLog) to Prevent Elderly Wandering in Hostels: A Three-Month Field Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2103.	1.2	12
923	Optogenetics: implications for Alzheimer's disease research and therapy. <i>Molecular Brain</i> , 2022, 15, 20.	1.3	14
924	Transcriptional response of murine microglia in Alzheimer's disease and inflammation. <i>BMC Genomics</i> , 2022, 23, 183.	1.2	11
925	The Added Value of Cerebrospinal Fluid Neurofilament Light Chain to Existing Diagnostic Methods and Biomarkers in a Mixed Memory Clinic Cohort of Consecutive Patients. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 121-127.	1.2	2
926	Computed Tomography Density and $\hat{1}^2$ -Amyloid Deposition of Intraorbital Optic Nerve May Assist in Diagnosing Mild Cognitive Impairment and Alzheimer's Disease: A ^{18}F -Flutemetamol Positron Emission Tomography/Computed Tomography Study. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 836568.	1.7	1
927	Alzheimer's disease "the journey of a healthy brain into organ failure. <i>Molecular Neurodegeneration</i> , 2022, 17, 18.	4.4	41
928	APOE Antibody Inhibits $\hat{1}^2$ -Associated Tau Seeding and Spreading in a Mouse Model. <i>Annals of Neurology</i> , 2022, 91, 847-852.	2.8	11
929	Neuroprotective Effects of Green Tea Seed Isolated Saponin Due to the Amelioration of Tauopathy and Alleviation of Neuroinflammation: A Therapeutic Approach to Alzheimer's Disease. <i>Molecules</i> , 2022, 27, 2079.	1.7	6
930	Molecular Insights into Therapeutic Potentials of Hybrid Compounds Targeting Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2022, 59, 3512-3528.	1.9	15
931	$\hat{1}^3$ -Secretase in Alzheimer's disease. <i>Experimental and Molecular Medicine</i> , 2022, 54, 433-446.	3.2	67

#	ARTICLE	IF	CITATIONS
932	On the relationships between epilepsy, sleep, and Alzheimer's disease: A narrative review. <i>Epilepsy and Behavior</i> , 2022, 129, 108609.	0.9	8
934	Roles and Mechanisms of the Protein Quality Control System in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 345.	1.8	12
935	Ketogenic diet ameliorates cognitive impairment and neuroinflammation in a mouse model of Alzheimer's disease. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 580-592.	1.9	39
936	siRNA Mediated GSK3 β Knockdown Targets Insulin Signaling Pathway and Rescues Alzheimer's Disease Pathology: Evidence from <i>In Vitro</i> and <i>In Vivo</i> Studies. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 69-93.	4.0	9
937	The Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 577-598.	0.8	4
938	Eriodictyol and Homoeriodictyol Improve Memory Impairment in A β ₂₅₋₃₅ -Induced Mice by Inhibiting the NLRP3 Inflammasome. <i>Molecules</i> , 2022, 27, 2488.	1.7	13
939	Cognitive disorder and dementia in type 2 diabetes mellitus. <i>World Journal of Diabetes</i> , 2022, 13, 319-337.	1.3	27
945	Exploring the Therapeutic Potential of Phytochemicals in Alzheimer's Disease: Focus on Polyphenols and Monoterpenes. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	18
946	Alzheimer Disease Prediction Using Learning Algorithms. <i>Smart Innovation, Systems and Technologies</i> , 2022, , 331-339.	0.5	1
947	Molecular Insights into Cell Type-specific Roles in Alzheimer's Disease: Human Induced Pluripotent Stem Cell-based Disease Modelling. <i>Neuroscience</i> , 2023, 518, 10-26.	1.1	5
948	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	3.7	20
949	Interventions to Improve the Oral Hygiene of Individuals with Alzheimer's Disease: A Systematic Review. <i>Dentistry Journal</i> , 2022, 10, 92.	0.9	3
950	Molecular details of aluminium-amyloid β peptide interaction by nuclear magnetic resonance. <i>BioMetals</i> , 2022, 35, 759-769.	1.8	1
951	Sustained Trem2 stabilization accelerates microglia heterogeneity and A β pathology in a mouse model of Alzheimer's disease. <i>Cell Reports</i> , 2022, 39, 110883.	2.9	20
952	N-terminally truncated A β _{24-x} proteoforms and their relevance for Alzheimer's pathophysiology. <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	7
954	Cerebral A β deposition in an A β -precursor protein-transgenic rhesus monkey. <i>Aging Brain</i> , 2022, 2, 100044.	0.7	2
955	Carbohydrate-derived bicyclic selenazolines as new dual inhibitors (cholinesterases/OGA) against Alzheimer's disease. <i>Bioorganic Chemistry</i> , 2022, 127, 105983.	2.0	5
956	RNA induces unique tau strains and stabilizes Alzheimer's disease seeds. <i>Journal of Biological Chemistry</i> , 2022, 298, 102132.	1.6	19

#	ARTICLE	IF	CITATIONS
957	A shared disease-associated oligodendrocyte signature among multiple CNS pathologies. <i>Nature Neuroscience</i> , 2022, 25, 876-886.	7.1	84
958	Differentially Aquaporin 5 Expression in Submandibular Glands and Cerebral Cortex in Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 1645.	1.4	4
959	Drosophila Innate Immunity Involves Multiple Signaling Pathways and Coordinated Communication Between Different Tissues. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	33
960	HEBP1 - An early trigger for neuronal cell death and circuit dysfunction in Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2023, 139, 102-110.	2.3	6
961	Posterior pole analysis and ganglion cell layer measurements in Alzheimer's disease. <i>Hospital Practice (1995)</i> , 0, , .	0.5	3
962	Rethinking common solvents in butyrylcholinesterase activity assays. <i>Inorganic Chemistry Communication</i> , 2022, 143, 109796.	1.8	0
963	The role of amyloid β^2 in the pathological mechanism of GNE myopathy. <i>Neurological Sciences</i> , 2022, 43, 6309-6321.	0.9	3
964	[18F]ROStrace detects oxidative stress in vivo and predicts progression of Alzheimer's disease pathology in APP/PS1 mice. <i>EJNMMI Research</i> , 2022, 12, .	1.1	3
966	CD33 isoforms in microglia and Alzheimer's disease: Friend and foe. <i>Molecular Aspects of Medicine</i> , 2023, 90, 101111.	2.7	18
967	Effects of Acute Sepsis on Cellular Dynamics and Amyloid Formation in a Mouse Model of Alzheimer's Disease. <i>Current Issues in Molecular Biology</i> , 2022, 44, 3822-3834.	1.0	1
968	New insights into macrophage subsets in atherosclerosis. <i>Journal of Molecular Medicine</i> , 2022, 100, 1239-1251.	1.7	3
969	Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. <i>MABs</i> , 2022, 14, .	2.6	5
970	Retinal Vascular Physiology Biomarkers in a 5XFAD Mouse Model of Alzheimer's Disease. <i>Cells</i> , 2022, 11, 2413.	1.8	3
971	MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal function in a model of Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2022, 27, 4770-4780.	4.1	19
972	Profiling Microglia through Single-Cell RNA Sequencing over the Course of Development, Aging, and Disease. <i>Cells</i> , 2022, 11, 2383.	1.8	13
973	Focal-type, but not Diffuse-type, Amyloid Beta Plaques are Correlated with Alzheimer's Neuropathology, Cognitive Dysfunction, and Neuroinflammation in the Human Hippocampus. <i>Neuroscience Bulletin</i> , 2022, 38, 1125-1138.	1.5	8
974	Cornuside Is a Potential Agent against Alzheimer's Disease via Orchestration of Reactive Astrocytes. <i>Nutrients</i> , 2022, 14, 3179.	1.7	8
975	Pathophysiological Association Between Diabetes Mellitus and Alzheimer's Disease. <i>Cureus</i> , 2022, , .	0.2	1

#	ARTICLE	IF	CITATIONS
976	Breathing disorders in neurodegenerative diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, , 223-239.	1.0	0
977	Alzheimer's Disease as a Disease of Evolutionary Mismatch, with a Focus on Reproductive Life History. , 2022, , 260-275.		0
978	SPIN90 Deficiency Ameliorates Amyloid β^2 Accumulation by Regulating APP Trafficking in AD Model Mice. International Journal of Molecular Sciences, 2022, 23, 10563.	1.8	0
979	Mechanistic Role of Jak3 in Obesity-Associated Cognitive Impairments. Nutrients, 2022, 14, 3715.	1.7	2
981	The reduction of astrocytic tau prevents amyloid- β^2 -induced synaptotoxicity. Brain Communications, 2022, 4, .	1.5	2
982	Use of electroencephalogram, gait, and their combined signals for classifying cognitive impairment and normal cognition. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
983	Alzheimer's Disease as a Disease of Evolutionary Mismatch, with a Focus on Reproductive Life History. , 2022, , 260-275.		2
984	PLC β^2 impacts microglia-related effectors revealing variants and pathways important in Alzheimer's disease. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	2
985	A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's disease. Science Translational Medicine, 2022, 14, .	5.8	33
986	Correlation between retinal vessel rarefaction and psychometric measures in an older Southern Italian population. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
987	The mechanism of Girdin in degenerative brain disease caused by high glucose stimulation. Frontiers in Endocrinology, 0, 13, .	1.5	0
988	Müller cell degeneration and microglial dysfunction in the Alzheimer's retina. Acta Neuropathologica Communications, 2022, 10, .	2.4	11
989	Influence of endogenous estrogen on a network model of female brain integrity. Aging Brain, 2022, 2, 100053.	0.7	0
990	Chronic TREM2 activation exacerbates β^2 -associated tau seeding and spreading. Journal of Experimental Medicine, 2023, 220, .	4.2	43
991	Metabolomic and lipidomic signatures in autosomal dominant and late-onset Alzheimer's disease brains. Alzheimer's and Dementia, 2023, 19, 1785-1799.	0.4	7
992	Extravaganza of Nanobiotechnology in the Diagnosis and Treatment of Dementia Patients. Current Pharmaceutical Biotechnology, 2022, 24, .	0.9	0
993	Evaluation of the Predictive Ability and User Acceptance of Panoramix 2.0, an AI-Based E-Health Tool for the Detection of Cognitive Impairment. Electronics (Switzerland), 2022, 11, 3424.	1.8	2
994	Sesquiterpenoids from the rhizomes of Homalomena pendula (Blume) Bakh.f showing acetylcholinesterase inhibitory activity: in vitro and in silico studies. Chemical Papers, 2023, 77, 1573-1581.	1.0	1

#	ARTICLE	IF	CITATIONS
995	Emerging roles of innate and adaptive immunity in Alzheimer's disease. <i>Immunity</i> , 2022, 55, 2236-2254.	6.6	49
996	TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4. <i>Neuron</i> , 2023, 111, 202-219.e7.	3.8	29
997	Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer's disease. <i>Brain Research</i> , 2023, 1799, 148171.	1.1	9
998	Modeling menopause and dementia in rodents: Investigations on cognition and coordination. , 2023, , 57-63.		0
999	Intercommunication between metal ions and amyloidogenic peptides or proteins in protein misfolding disorders. <i>Coordination Chemistry Reviews</i> , 2023, 478, 214978.	9.5	7
1000	Cerebrospinal fluid glucose is not altered in patients with dementia. <i>Clinical Biochemistry</i> , 2023, 112, 1-5.	0.8	0
1001	3T sodium MR imaging in Alzheimer's disease shows stage-dependent sodium increase influenced by age and local brain volume. <i>NeuroImage: Clinical</i> , 2022, 36, 103274.	1.4	1
1002	PGCLCs of human 45,XO reveal pathogenetic pathways of neurocognitive and psychosocial disorders. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	1
1003	Applications of Carbon Dots for the Treatment of Alzheimer's Disease. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 6621-6638.	3.3	4
1004	Effects of multi-mode physical stimulation on APP/PS1 Alzheimer's disease model mice. <i>Heliyon</i> , 2022, 8, e12366.	1.4	1
1005	The transcriptomic landscape of neurons carrying PSEN1 mutations reveals changes in extracellular matrix components and non-coding gene expression. <i>Neurobiology of Disease</i> , 2023, 178, 105980.	2.1	6
1006	The Mechanism of Two Benzaldehydes from <i>Aspergillus terreus</i> C23-3 Improve Neuroinflammatory and Neuronal Damage to Delay the Progression of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 905.	1.8	1
1007	Animal toxins: As an alternative therapeutic target following ischemic stroke condition. <i>Life Sciences</i> , 2023, 317, 121365.	2.0	0
1008	Comparison of Two Varieties Fig (Peggy Red and Green) Peel Extracts by Liquid Chromatography-Tandem Mass Spectrometry Analysis and for Neuroprotective Efficacy in <i>Caenorhabditis elegans</i> . <i>Journal of Medicinal Food</i> , 2023, 26, 14-26.	0.8	1
1009	Early Mitochondrial Defects in the 5xFAD Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2023, , 1-16.	1.2	1
1010	An intracerebroventricular injection of A β (1-42) modifies temporal profiles of spatial memory performance and oxidative status in the temporal cortex rat. <i>Brain Research</i> , 2023, , 148242.	1.1	0
1011	Electroacupuncture Ameliorates Cognitive Impairment by Regulating $\hat{3}$ -Amino Butyric Acidergic Interneurons in the Hippocampus of 5 \hat{A} Familial Alzheimer's Disease Mice. <i>Neuromodulation</i> , 2023, , .	0.4	4
1012	Insomnia Symptoms and Biomarkers of Alzheimer's Disease in the Community. <i>Journal of Alzheimer's Disease</i> , 2023, 91, 1423-1434.	1.2	1

#	ARTICLE	IF	CITATIONS
1014	Data-Driven Phenotyping of Alzheimer's Disease under Epigenetic Conditions Using Partial Volume Correction of PET Studies and Manifold Learning. <i>Biomedicines</i> , 2023, 11, 273.	1.4	0
1015	Synthesis, structural characterization and study of antioxidant and anti-PrPSc properties of flavonoids and their rhenium(I)tricarbonyl complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2023, 28, 235-247.	1.1	2
1016	Comparison of Oleocanthal-Low EVOO and Oleocanthal against Amyloid- β^2 and Related Pathology in a Mouse Model of Alzheimer's Disease. <i>Molecules</i> , 2023, 28, 1249.	1.7	6
1017	SorCS1 inhibits amyloid- β^2 binding to neurexin and rescues amyloid- β^2 -induced synaptic pathology. <i>Life Science Alliance</i> , 2023, 6, e202201681.	1.3	5
1018	The Eye as a Diagnostic Tool for Alzheimer's Disease. <i>Life</i> , 2023, 13, 726.	1.1	2
1019	Prevalence of sleep-related breathing disorders and associated risk factors among people with dementia: A meta-analysis. <i>Sleep Medicine</i> , 2023, 103, 51-61.	0.8	6
1020	Lipids uniquely alter the secondary structure and toxicity of amyloid beta 1-42 aggregates. <i>FEBS Journal</i> , 2023, 290, 3203-3220.	2.2	21
1021	Imaging Amyloid and Tau in the Retina: Current Research and Future Directions. <i>Journal of Neuro-Ophthalmology</i> , 2023, 43, 168-179.	0.4	3
1022	Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study. <i>Brain</i> , 2023, 146, 2275-2284.	3.7	20
1023	Structural Proteomic Profiling of Cerebrospinal Fluids to Reveal Novel Conformational Biomarkers for Alzheimer's Disease. <i>Journal of the American Society for Mass Spectrometry</i> , 2023, 34, 459-471.	1.2	0
1024	The Effect of a Novel Mica Nanoparticle, STB-MP, on an Alzheimer's Disease Patient-Induced PSC-Derived Cortical Brain Organoid Model. <i>Nanomaterials</i> , 2023, 13, 893.	1.9	5
1025	Low Ankle-Brachial Index Relates to Alzheimer-Signature Cerebral Glucose Metabolism in Cognitively Impaired Older Adults. <i>Journal of Alzheimer's Disease</i> , 2023, 93, 87-95.	1.2	1
1026	S100B chaperone multimers suppress the formation of oligomers during A β^2 aggregation. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	7
1027	PARP16-Mediated Stabilization of Amyloid Precursor Protein mRNA Exacerbates Alzheimer's Disease Pathogenesis. , 2023, .		1
1028	Sleep Disturbances Generate Alzheimer's Disease Through Inflammation. , 0, 36, 261-268.		0
1029	Autophagic Mechanisms in Longevity Intervention: Role of Natural Active Compounds. <i>Expert Reviews in Molecular Medicine</i> , 0, , 1-41.	1.6	0
1030	Role of Microbiota-Modified Bile Acids in the Regulation of Intracellular Organelles and Neurodegenerative Diseases. <i>Genes</i> , 2023, 14, 825.	1.0	3
1031	Ketogenic Diet as a Promising Non-Drug Intervention for Alzheimer's Disease: Mechanisms and Clinical Implications. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 1173-1198.	1.2	3

#	ARTICLE	IF	CITATIONS
1032	Myricetin improves pathological changes in 3 \times Tg-AD mice by regulating the mitochondria-NLRP3 inflammasome-microglia channel by targeting P38 MAPK signaling pathway. <i>Phytomedicine</i> , 2023, 115, 154801.	2.3	7
1033	Deciphering mechanisms of action of ACE inhibitors in neurodegeneration using <i>Drosophila</i> models of Alzheimer's disease. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	3
1034	Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7258.	1.8	7
1044	Alzheimer's Disease Prediction with K-means Clustering and Reinforcement Learning Approach. , 2023, , .		0
1050	Human 3D brain organoids: steering the demolecularization of brain and neurological diseases. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	5
1053	Emerging trends in IRAK-4 kinase research. <i>Molecular Biology Reports</i> , 0, , .	1.0	0
1071	BIN1 in the Pursuit of Ousting the Alzheimer's Reign: Impact on Amyloid and Tau Neuropathology. <i>Neurotoxicity Research</i> , 0, , .	1.3	0
1078	Molecular Pathology of the Central Nervous System. , 2023, , 615-658.		0
1083	Identifying Candidate Biomarkers for Alzheimer's Disease Diagnoses Using Saliva ^{1}H NMR-Based Metabolomics. <i>Lecture Notes in Networks and Systems</i> , 2023, , 585-593.	0.5	0
1096	Pathological phenotypes of astrocytes in Alzheimer's disease. <i>Experimental and Molecular Medicine</i> , 2024, 56, 95-99.	3.2	0